Disposition of PF-07321332 (Nirmatrelvir), an Orally Bioavailable Inhibitor of SARS-CoV-2 3CL Protease, across Animals and Humans

Heather Eng¹, Alyssa L. Dantonio¹, Eugene P. Kadar¹, R. Scott Obach¹, Li Di¹, Jian Lin¹, Nandini C. Patel², Britton Boras³, Gregory S. Walker¹, Jonathan J. Novak⁴,¹, Emi Kimoto¹, Ravi Shankar P. Singh², and Amit S. Kalgutkar²

Affiliations:

¹Pfizer Worldwide Research, Development & Medical; Groton, CT 06340, USA

²Pfizer Worldwide Research, Development & Medical; Cambridge, MA 02139, USA

³Pfizer Worldwide Research, Development & Medical; La Jolla, CA 92121, USA
Running Title: Pharmacokinetics and metabolism of Nirmatrelvir

Corresponding Author: Amit S. Kalgutkar, Ph.D.; amit.kalgutkar@pfizer.com; Tel. (617)-551-3336

Orcid ID:

Amit Kalgutkar: https://orcid.org/0000-0001-9701-756X
Li Di: https://orcid.org/0000-0001-6117-9022
Heather Eng: https://orcid.org/0000-0002-2914-3967
Emi Kimoto: https://orcid.org/0000-0003-1284-2769
Eugene Kadar: https://orcid.org/0000-0003-3724-6517
R Scott Obach: https://orcid.org/0000-0002-6604-401X
Nandini C. Patel http://orcid.org/0000-0002-2735-7662
Alyssa Dantonio: https://orcid.org/0000-0001-9067-3660
Ravi Shankar P Singh: https://orcid.org/0000-0001-6298-8219

Number of text pages (including references): 45
Number of words in the abstract: 250
Number of words in the introduction: 650
Number of words in the discussion: 1318
Number of references: 43
Number of tables: 5
Number of figures: 7
Abbreviations:

SARS-CoV, severe acute respiratory syndrome coronavirus; MERS-CoV, Middle East respiratory syndrome coronavirus, COVID-19, coronavirus disease 2019; 3CL\textsuperscript{pro}, 3C-like protease; PF-00835231, N-\{(1S)-1-\{[((1S)-3-hydroxy-2-oxo-1-{[(3S)-2-oxopyrrolidin-3-yl]-methyl}propyl)amino]carbonyl\}-3-methylbutyl\}-4-methoxy-1\textit{H}-indole-2-carboxamide; iv, intravenous; PF-07321332, (nirmatrelvir, 1R,2S,5S)-N-\{(1S)-1-Cyano-2-{[(3S)-2-oxopyrrolidin-3-yl]ethyl\}-6,6-dimethyl-3-[3-methyl-N-(trifluoroacetyl)-L-valyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide; \(K\textsubscript{i}\), inhibition constant; dNHBE, differentiated normal human bronchial epithelial cells; EC\textsubscript{90}, 90% effective concentration; po, oral; PK, pharmacokinetics; CYP, cytochrome P450; DMSO, dimethyl sulfoxide; LC-MS/MS, liquid chromatography tandem mass spectrometry; MTBE, methyl-tert-butyl ether; SGF, simulated gastric fluid; SIF, simulated intestinal fluid; HIF, human intestinal fluid; SCHH, sandwich-cultured human hepatocytes; HBSS, Hanks balanced salt solution; CL\textsubscript{-biliary,int.app}, apparent intrinsic biliary clearance; CL\textsubscript{-biliary}, biliary clearance; HLM, human liver microsomes; NADPH, \(\beta\)-Nicotinamide adenine dinucleotide phosphate, reduced form; ROE, rotating Overhauser effect; \(V\textsubscript{max}\), maximal velocity; \(K\textsubscript{M}\), substrate concentration at half-maximal velocity; CL\textsubscript{-int.app}, apparent intrinsic clearance; CL\textsubscript{-int.app,scaled}, scaled apparent intrinsic clearance; \(f\textsubscript{u,mic}\), fraction unbound in liver microsomes; \(f\textsubscript{CL}\), fractional clearance; \(f\textsubscript{m}\), fraction metabolized; \(f\textsubscript{a}\), fraction of the po dose absorbed from the gastrointestinal lumen; CL\textsubscript{-renal}, renal clearance; V\textsubscript{dss}, steady state distribution volume; C\textsubscript{max}, maximal plasma concentration; T\textsubscript{max}, time to reach C\textsubscript{max}; AUC, area under the plasma concentration-time curve; \(t\textsubscript{1/2}\), half-life; P\textsubscript{-app}, apparent absorptive permeability; MDCKII-LE, low efflux Madin-Darby canine kidney cells; BCRP, breast cancer resistant protein; MDR1, multidrug resistant gene 1; \(f\textsubscript{u,p}\), plasma unbound fraction; BPR, blood to plasma ratio; CL\textsubscript{-hep}, in
vitro hepatic clearance; \( m/z^+ \), protonated molecular ion; CID, collision-induced dissociation; \( J \), coupling constant; HCD, high energy C-trap dissociation; HSQC, multiplicity edited heteronuclear single quantum coherence; CL\(_p\), plasma clearance; OAT, organic anion transporter; MATE, multidrug and toxin extrusion protein; OCT, organic cation transporter; OATP, organic anion transporting polypeptide; oral F, oral bioavailability; \( F_a \times F_g \), fraction of the oral dose absorbed; IC\(_{50}\), half-maximal inhibitory concentration; TDI, time-dependent inhibition; \( k_{\text{inact}} \), maximal rate of inactivation; \( K_I \), inactivator concentration required to achieve 50\% \( k_{\text{inact}} \); MI complex, metabolic-inhibitor complex; mRNA, messenger RNA; IND\(_{\text{max}}\), maximum fold induction; EC\(_{50}\), inducer concentration required to achieve 50\% IND\(_{\text{max}}\); HEK, human embryonic kidney cells; HBD, hydrogen bond donor count.
Abstract

The SARS-CoV-2 3C-like protease inhibitor PF-07321332 (nirmatrelvir), in combination with ritonavir (Paxlovid™), was recently granted emergency use authorization by multiple regulatory agencies for the treatment of COVID-19 in adults and pediatric patients. Disposition studies on nirmatrelvir in animals and in human reagents, which were used to support clinical studies are described, herein. Plasma clearance was moderate in rats (27.2 ml/min/kg) and monkeys (17.1 ml/min/kg), resulting in half-lives of 5.1 and 0.8 h, respectively. The corresponding oral bioavailability was moderate in rats (34–50%) and low in monkeys (8.5%), primarily due to oxidative metabolism along the gastrointestinal tract in this species. Nirmatrelvir demonstrated moderate plasma protein binding in rat, monkey, and human with mean unbound fractions ranging from 0.310–0.478. The metabolism of nirmatrelvir was qualitatively similar in liver microsomes and hepatocytes from rat, monkey, and human; prominent metabolites arose via cytochrome P450 (CYP) mediated oxidations on the P1 pyrrolidinone ring, P2 6,6-dimethyl-3-azabicyclo[3.1.0]hexane, and the tertiary-butyl group at the P3 position. Reaction phenotyping studies in human liver microsomes revealed that CYP3A4 was primarily responsible (fraction metabolized=0.99) for the oxidative metabolism of nirmatrelvir. Minor clearance mechanisms involving renal and biliary excretion of unchanged nirmatrelvir were also noted in animals, and in sandwich-cultured human hepatocytes. Nirmatrelvir was a reversible and time-dependent inhibitor as well as inducer of CYP3A activity in vitro. First-in-human pharmacokinetics studies have demonstrated a considerable boost in the oral systemic exposure of nirmatrelvir upon co-administration with the CYP3A4 inhibitor ritonavir, consistent with the predominant role of CYP3A4 in nirmatrelvir metabolism.
Significance Statement:

The manuscript describes the preclinical disposition, metabolism, and drug-drug interaction potential of PF-07321332 (nirmatrelvir), an orally active peptidomimetic-based inhibitor of the SARS-CoV-2 3CL protease, which has been granted emergency use authorization by multiple regulatory agencies across the globe for the treatment of COVID-19 in COVID-19-positive adults and pediatric patients, who are at high risk for progression to severe COVID-19, including hospitalization or death.
Introduction

Coronaviruses are a assorted family of RNA viruses, which can lead to respiratory, enteric, and neurological diseases in humans and animals (Hu et al., 2021). Emerging coronaviruses of human health concern include two highly infectious coronaviruses, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), which were detected in humans in 2002 and 2012, respectively (Cui et al., 2019). An novel coronavirus termed as SARS-CoV-2 recently appeared in Wuhan, China, and led to an outbreak of uncommon viral pneumonia (Zhu et al., 2020). With high transmission rates, this new disease (known as coronavirus disease 2019 (COVID-19)) has quickly spread globally, resulting in 366 million confirmed COVID-19 cases, and over 5.64 million deaths as of January 2022 (Coronavirus Death Toll and Trends - Worldometer (worldometers.info)). Isolation of the virus bronchoalveolar fluid from infected patients and genomic RNA sequencing indicated that the causative agent is a betacoronavirus, which was not encountered previously. Despite the novelty, the genomic sequence identity of SARS-CoV-2 is similar to the one coded for SARS-CoV (~79%) and MERS-CoV (~50%) (Lu et al., 2020).

The SARS-CoV-2 genome contains two open reading frames, which encode two large polyproteins (Ziebuhr et al., 1997; Zhou et al., 2020), from which functional proteins are generated through proteolysis. SARS-CoV-2 is known to encode a papain-like cysteine protease and a chymotrypsin-like cysteine protease known as main protease or 3C-like protease (3CL pro) (Jin et al., 2020; Pillaiyar et al., 2016). The coronavirus 3CL pro is a three-domain protease, containing a Cys145-His41 catalytic dyad between domains I and II (Anand et al., 2003; Yang et al., 2003). A common structural feature among 3CL pro substrates is the presence of a P1 Gln residue at the cleavage site, which is not encountered in any known human equivalent cysteine
protease. This observation presents an unique opportunity in designing small-molecule inhibitors of 3CLpro with relatively high selectivity over the human proteome (Rut et al., 2021).

During the 2002 SARS outbreak, we initiated efforts to identify small-molecule inhibitors of the SARS-CoV-1 3CLpro, which led to the design of N-((1S)-1-[[((1S)-3-hydroxy-2-oxo-1-((3S)-2-oxopyrrolidin-3-yl)-methyl]propyl)amino]carbonyl]-3-methylbutyl)-4-methoxy-1H-indole-2-carboxamide (PF-00835231, Figure 1) as a potent inhibitor of SARS-CoV-1, and more recently SARS-CoV-2 (Boras et al., 2021; Hoffman et al., 2020). The phosphate derivative (PF-07304814) of PF-00835231 is currently being studied as an intravenous (iv) treatment option in hospitalized COVID-19 patients (Boras et al., 2021). In response to the COVID-19 pandemic, we revitalized discovery efforts to identify orally active SARS-CoV-2 3CLpro inhibitors using PF-00835231 as a starting point. A key objective in this exercise was to improve upon the poor oral absorption characteristics of PF-00835231, while retaining the favorable inhibitory effects against SARS-CoV-2 in recombinant enzyme and cellular antiviral assays. This research activity culminated in the design of (1R,2S,5S)-N-((1S)-1-cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl)-6,6-dimethyl-3-[3-methyl-N-(trifluoroacetyl)-L-valyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide (PF-07321332, nirmatrelvir) as an orally active antiviral agent (Owen et al., 2021). Nirmatrelvir inhibited (inhibition constant ($K_i$) = 3.11 nM) recombinant SARS-CoV-2 3CLpro protease activity via a reversible covalent mechanism involving reaction of the cyano group with the catalytic Cys145 residue (see Figure 1). Nirmatrelvir also repressed SARS-CoV-2 replication in physiologically relevant cellular systems such as differentiated normal human bronchial epithelial (dNHBE) cells and human adenocarcinoma-derived alveolar basal epithelial cells with 90% effective unbound concentration ($EC_{90,u}$) values of 181 nM and 215 nM, respectively. Oral (po) administration of nirmatrelvir to a mouse-adapted SARS-CoV-2 model resulted in reduction
of lung viral titers in a dose-dependent fashion, and protected infected mice from lung tissue damage and weight loss (Owen et al., 2021). Preclinical disposition mechanisms of nirmatrelvir were characterized in animals and in human reagents to support animal safety and first-in-human clinical studies. The potential for pharmacokinetic (PK) interactions arising from inhibition/induction of major human cytochrome P450 (CYP) enzymes and drug transporters was also examined in vitro systems. The collective results, including the demonstration of the predominant role for CYP3A4 in nirmatrelvir metabolism, which presented an option of boosting nirmatrelvir systemic exposure in humans by utilizing the CYP3A4 inhibitor ritonavir, are described herein.

Materials and Methods

Chemicals and Materials. Nirmatrelvir (chemical purity > 99% by HPLC and NMR) was synthesized at Pfizer Inc. (Groton, CT). Stock solutions of nirmatrelvir were prepared in either 100% dimethyl sulfoxide (DMSO) or acetonitrile. Commercially obtained chemicals and solvents were of high-performance liquid chromatography or analytical grade. In vitro studies were conducted on human tissue, which was acquired from a third party, and was confirmed as compliant with Pfizer policies, including Institutional Review Board/Independent Ethics Committee approval. Animal PK studies were conducted in agreement with federal, state, local and institutional guidelines on the use of laboratory animals in research in AAALAC accredited facilities, and were approved by Pfizer’s or Bioduro’s (Shanghai, PRC) Institutional Animal Care and Use Committee. Description of experimental procedures for passive permeability, efflux, plasma protein/human liver microsomal binding, blood cell partitioning, liver microsome/hepatocyte stability, preclinical PK, CYP inhibition/induction and transporter
inhibition, and liquid chromatography tandem mass spectrometry (LC-MS/MS) assays for nirmatrelvir quantitation are provided as supplemental information.

**Aqueous Solubility and Dissolution Measurement.** Equilibrium solubility of crystalline nirmatrelvir in water was measured using an anhydrous form (‘form 1’) as well as a methyl-tert-butyl ether (MTBE) co-solvate form) in duplicate, utilizing a temperature cycling method (Murdande et al., 2009). Briefly, nirmatrelvir was weighed in a screw top vial and an appropriate amount of water (≥ 0.5 ml) was added. The vial was placed in an Environ-Genie incubator (Scientific Industries, Bohemia, New York) and a temperature cycling program (8 h at 40 °C, 5 h at 15 °C, followed by 12 h at 25 °C) was applied. After a pH measurement, the solutions were centrifuged (5 min, 14000 rpm) for particulate separation, and the supernatants assayed by ultraperformance liquid chromatography for nirmatrelvir concentrations. Dissolution studies (Murdande et al., 2009) were performed with nirmatrelvir (150 mg, MTBE co-solvate or anhydrous ‘form 1’) in distilled water or 0.1 N HCl (500 ml), using a suspension of well-dispersed nirmatrelvir particles in 0.5% w/v methyl cellulose. A dissolution test was conducted using a USP II dissolution apparatus (rotating at 100 rpm) with in-situ fiber optic UV-visible spectroscopy (Distek, Inc., North Brunswick, NJ).

**Metabolic Stability in Intestinal Fluid.** Fresh simulated gastric fluid (SGF) and simulated intestinal fluid (SIF) were prepared in-house according to the United States Pharmacopeia National Formulary ([https://online.uspnf.com/uspnf/document/1_GUID-190BB90A-8350-41D4-82E0-88920705A993_1_en-US](https://online.uspnf.com/uspnf/document/1_GUID-190BB90A-8350-41D4-82E0-88920705A993_1_en-US); [https://online.uspnf.com/uspnf/document/1_GUID-4A435135-EDA6-4309-B967-0CE322595823_1_en-US](https://online.uspnf.com/uspnf/document/1_GUID-4A435135-EDA6-4309-B967-0CE322595823_1_en-US)). SGF was a solution of 3.2 g/l of pepsin and NaCl dissolved in deionized water (pH 1.2). SIF was a suspension of 10 g/l of pancreatin in monobasic potassium phosphate dissolved in deionized water (pH 6.8). Human intestinal fluid (HIF)
(National BioService LLC, Saint-Petersburg, Russia) was a mixture of pancreatic juice and bile obtained directly from the duodenum of two fasted adult volunteers via a surgical probe. An aliquot of SGF, SIF, or HIF was prewarmed to 37 °C for 5 min followed by the addition of 1 µM nirmatrelvir (0.5% organic in final incubation, 200 µl final incubation volume). Incubations were conducted in duplicate or triplicate. At various time points (0.25, 10, 20, 40, 60, 90, and 120 min), a 20 µl aliquot of the incubation mixture was removed and quenched with acetonitrile (100 µl) containing diclofenac (25 ng/ml) as internal standard. Samples were vortexed, centrifuged (5 min, 2300 x g) and the supernatant (50 µl) was diluted with 200 µl of water. Quantitation of nirmatrelvir in the samples was performed using LC-MS/MS.

**Biliary Excretion in Sandwich Cultured Human Hepatocytes (SCHH).** Plateable cryopreserved human hepatocytes lot Hu4165 (female, Caucasian, age 57) were purchased from Invitrogen (Waltham, MA). The SCHH methodology and data analysis applied here were described previously (Bi et al., 2006; Kimoto et al., 2017). Briefly, hepatocytes were plated in collagen-coated 24-well plates on day 1 at a density of 0.375 × 10^6 cells/well and overlaid with ice-cold matrigel after 18-24 h of incubation. On day 5, SCHH were first rinsed twice with Hanks balanced salt solution (HBSS) containing Ca^{2+}/Mg^{2+} (standard) or Ca^{2+}/Mg^{2+}-free HBSS, and then preincubated for 10 min with standard or Ca^{2+}/Mg^{2+}-free HBSS at 37 °C. After aspirating the preincubation buffer, uptake was initiated by adding prewarmed nirmatrelvir (0.5 µM) to 37 °C and terminated at a designated time (10 and 20 min) by adding ice-cold standard HBSS. Hepatocytes were lysed with methanol containing an internal standard for quantification of PF-07321332 by LC-MS/MS. The in vitro apparent intrinsic biliary clearance (CL_{biliary,int,app}) was scaled up to a whole liver after application of physiological scalars of (120 × 10^6 cells/g liver).
liver) × (21 g liver/kg body weight) to estimate the human biliary clearance (CL_{biliary}) (Kimoto et al., 2017).

**Metabolite Identification.** Nirmatrelvir (10 μM) was incubated in Wistar-Han rat (male and female), Cynomolgus monkey (male), and pooled (mixed sex of 50) human liver microsomes (HLM) (protein concentration = 2 mg/ml) (Sekisui XenoTech (Kansas City, KS)) or recombinant human CYP enzymes (CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2D6, CYP2E1, CYP2J2, CYP3A4, CYP3A5, CYP3A7, and CYP4F2 100 pmol/ml each) (Corning, Glendale, AZ) in 100 mM potassium phosphate buffer (pH 7.4) containing β-nicotinamide adenine dinucleotide phosphate, reduced form (NADPH) (1.3 mM), MgCl2 (3.3 mM) at 37 °C for 1 h. Incubations were quenched with acetonitrile (0.6 ml). Because nirmatrelvir possesses very poor UV absorbance, a second set of incubations were generated where the parent compound was only added after the acetonitrile quench. These incubations mixtures, used to assess metabolite formation by HPLC-UV, ensured an improved delineation of nirmatrelvir-related material from other components in the incubations. The quenched incubation mixtures were centrifuged (5 min, 1800 x g) and the supernatants were evaporated to dryness.

Metabolite identification in hepatocytes was performed in nirmatrelvir (10 μM) incubations with Wistar-Han rat (male, pool of 24 animals), cynomolgus monkey (male, pool of 3 animals), and human (pool of 13 donors of mixed sex) hepatocytes (BioIVT, Baltimore, MD) at 0.75 x 10^6 cells/ml. Periodic aliquots were removed at 0, 1, and 4 h, and quenched with 5 volumes of acetonitrile. Samples were centrifuged (5 min, 1800 x g) and evaporated to dryness using a Genevac evaporative centrifuge.

**LC-MS/MS Analysis for Metabolite Identification.** The residues were reconstituted in 50–150 μl of 1% formic acid containing 20% acetonitrile and analyzed by ultra-high performance liquid
chromatography-UV-high resolution mass spectrometry operated in positive ion mode using an Orbitrap Elite mass spectrometer in line with a Vanquish HPLC-UV with cooled autoinjector (Thermofisher, Waltham, MA). Injection volumes were 5 to 15 μl, depending on the experimental run. A Kinetex XB C18 column (Phenomenex, Torrance, California) was used (2.1 x 100 mm, 2.6 μm) with a flow rate of 0.4 ml/min heated to 45 °C. Mobile phase A was comprised of 0.1% formic acid in water and mobile phase B was comprised of acetonitrile. The mobile phase composition began at 5% B held for 0.5 min followed by a linear gradient to 70% B at 11 min, a second linear gradient to 95% B at 13 min, a 1 min wash at 95% B, and finally a 2 min re-equilibration period at 5% B. UV was monitored between 200 to 400 nm and chromatograms were reconstructed using λ at 200 nm.

**Biosynthesis of Nirmatrelvir Metabolites for Structural Elucidation.** Nirmatrelvir (25 μM), HLM (2 mg/ml), MgCl₂ (3.3 mM), and NADPH (1.3 mM) were incubated in potassium phosphate buffer (100 mM, pH 7.4) (40 ml) at 37 °C for 55 min followed by the addition of acetonitrile (40 ml). The solution was centrifuged (1800 x g) for 5 min and concentrated in a Genevac vacuum centrifuge. The remaining mixture was treated with acetonitrile (0.5 ml), formic acid (0.5 ml), and water to a volume of 50 ml. This mixture was centrifuged (30 min, 40000 x g) and the supernatant was injected into a Polaris C18 column (Agilent, Santa Clara, CA) (4.6 x 250 mm; 5 μm) through a Jasco HPLC pump (Jasco Inc., Easton, MD) at 0.8 ml/min. After injection, the column was moved to an Acquity HPLC-UV in line with a CTC Analytics fraction collector (Zwingen, Switzerland) and linear trap quadrupole Velos mass spectrometer (ThermoFisher, Waltham, MA). The material was eluted with a mobile phase A (0.1% formic acid in water) and mobile phase B (acetonitrile) at a flow rate of 0.8 ml/min. The gradient was initiated at 2% mobile phase B with a linear gradient to 15% mobile phase B at 5 min, a second
linear gradient to 60% mobile phase B at 85 min, and a third linear gradient to 95% mobile phase B at 90 min. This composition was held for 9 min followed by a 10 min reequilibration period to initial conditions. The eluent was passed through the UV detector, then a splitter that directed the flow to the fraction collector and mass spectrometer in an approximate 15:1 ratio. Fractions were collected every 20 seconds and those containing metabolites of interest were evaluated for purity by ultrahigh pressure LC-MS with UV detection described above to facilitate pooling. Pooled fractions were evaporated in a vacuum centrifuge and residues evaluated by NMR spectroscopy for structural elucidation.

**NMR Spectroscopy.** Samples were dissolved in DMSO-d$_6$ “100%” (0.045 ml) (Cambridge Isotope Laboratories, Andover, MA) and placed in a NMR tube (1.7 mm) in a dry argon atmosphere. $^1$H and $^{13}$C spectra were referenced using residual DMSO-d$_6$ ($^1$H $\delta = 2.50$ parts per million relative to tetramethylsilane, $\delta = 0.00$, $^{13}$C $\delta = 39.50$ parts per million relative to tetramethylsilane, $\delta = 0.00$). NMR spectra were recorded on a Bruker Avance 600 MHz (Bruker BioSpin Corporation, Billerica, MA) controlled by Topspin V4.0 and equipped with a 1.7 mm TCI Cryo probe. 1D spectra were recorded using an approximate sweep width of 8400 Hz and a total recycle time of approximately 7 s. The resulting time-averaged free induction decays were transformed using an exponential line broadening of 1.0 Hz to enhance signal to noise. For through-space experiments (rotating-frame Overhauser effect (ROE) or nuclear Overhauser effect) the sample temperature was raised to 340 K. Two dimensional NMR data were recorded using the standard pulse sequences provided by Bruker. At minimum, a 1K x 128 data matrix was acquired using a minimum of 2 scans and 16 dummy scans with a spectral width of 10000 Hz in the f2 dimension. The 2D data sets were zero-filled to at least 1k data point. Post-
acquisition data processing was performed with either Topspin V3.2 or MestReNova V9.1. A series of standard 1D and 2D NMR experiments were performed on each sample.

**Enzyme Kinetics of Nirmatrelvir Metabolite Formation in HLM.** Experimental conditions used in the kinetics study design were chosen to yield linear reaction velocities as determined from preliminary range finding experiments. To determine the rates of metabolite formation, nirmatrelvir (0.02–200 µM) was incubated with HLM (pool of 50 mixed gender donors; Sekisui XenoTech, Kansas City, KS) diluted to 0.3 mg/ml microsomal protein in 100 mM potassium phosphate buffer (pH 7.4) supplemented with MgCl₂ (3.3 mM) and NAPDH (1.3 mM) for a final incubation volume of 300 µl. nirmatrelvir stock solutions were prepared by serial dilution in acetonitrile such that the final concentration of acetonitrile in the incubations was 1.0%. Incubations were conducted at 37 °C in duplicate. After 15 min, aliquots of the incubation mixture (200 µl) were quenched with acetonitrile (600 µl) containing internal standard (25 ng/ml diclofenac). Samples were vortexed, centrifuged (5 min, 2300 x g), and the supernatant was diluted with an equal volume of water. Samples were analyzed by LC-MS/MS for quantitation of nirmatrelvir oxidative metabolites M1 (PF-07329265), M2 (PF-07329266), M3 (PF-07329267), and M4 (PF-07329268) for which authentic standards were available through biochemical synthesis.

The LC-MS/MS system consisted of a Sciex Triple Quadrupole 5500 mass spectrometer (Sciex, Framingham, MA), equipped with an electrospray ion source and Agilent 1290 binary pump (Agilent Technologies, Santa Clara, CA). Aqueous mobile phase (A) was composed of water with 0.1% formic acid and organic mobile phase (B) consisted of acetonitrile with 0.1% formic acid. Samples (10 µl) from various in vitro incubations were injected onto a Kinetex XB-C18 (2.1 x 50 mm, 2.6 µm) (Phenomenex, Torrance, CA) column maintained at room
temperature with a flow rate of 0.5 ml/min. The gradient program began with 10% mobile phase B held for 0.2 min, followed by a linear gradient to 40% B over 2.3 min, then to 98% over 0.3 min, held at 98% B for 0.6 min followed by re-equilibration to initial conditions for 0.3 min. The mass spectrometer was operated in positive detection mode with the following analyte mass transitions (Q1/Q3): diclofenac 296/250, nirmatrelvir 500/110, PF-07329265 (M1) 516/126, PF-07329266 (M2) 516/289, PF-07329267 (M3) 516/291, and PF-07329268 (M4) 498/110 (optimized Q1 mass representing loss of H$_2$O in the source). The range of analyte concentration for standard curve was 0.25–250 nM (M1 and M4) and 0.25–100 nM (M2 and M3). Integration and quantitation of metabolite and internal standard peak areas were performed using Analyst version 1.7 (Sciex, Framingham, MA) to derive the analyte to internal standard peak area ratios. Standard curves for the quantitation of metabolite concentration were prepared from plots of concentration versus area ratio and analyzed using a linear regression with 1/x$^2$ weighting.

**Data Analysis** Formation rates ($v$) were calculated by dividing the measured metabolite concentration by incubation time and protein concentration of the incubation. The Michaelis-Menten model was used to derive the apparent enzyme kinetic parameters $V_{\text{max}}$ (maximal velocity) and $K_M$ (substrate concentration at half-maximal velocity) using GraphPad Prism version 8.02 (La Jolla, CA):

$$ v = \frac{V_{\text{max}} \times S}{K_M + S} $$

Assessment of the enzyme kinetics was conducted by visual inspection of the Eadie-Hofstee diagrams constructed from the plot of $v$ versus the ratio of $v$ and substrate concentration (Nagar et al., 2014):

$$ v = -K_M \left( \frac{v}{S} \right) + V_{\text{max}} $$
When observations of nonlinear kinetics in Eadie-Hofstee plots for metabolite formation data were suggestive of multi-enzyme contribution, fitting to a two-enzyme non-saturable Michaelis-Menten model was attempted:

\[ v = \left( \frac{V_{\text{max}1} \times S}{K_{M1} + S} \right) + \left( \text{CL}_{\text{int}(2)} \times S \right) \]

where subscript 1 represents a high-affinity/low-capacity enzyme and CL\(_{\text{int}(2)}\) represents the apparent intrinsic clearance rate of the secondary low-affinity/high-capacity enzyme (Nagar et al., 2014).

Alternately, for metabolite formation profiles showing characteristics of allosteric sigmoidal in the Eadie-Hofstee plots, the following equation was used to fit the data:

\[ v = \left( \frac{V_{\text{max}} \times S^h}{K_{\text{half}}^h + S^h} \right) \]

where \(K_{\text{half}}\) is the enzyme concentration that gives a half maximal velocity, and \(h\) is the Hill slope. Assessment of best fit was based on a number of criteria, including visual inspection of the data plots (Michaelis-Menten and Eadie-Hofstee), distribution of the residuals, size of the sum of the squared residuals, and the standard error of the estimates. Selection of a model other than Michaelis-Menten was based on the F-test (\(p < 0.05\)) or the Akaike Information Criterion (Nagar et al., 2014). In vitro apparent intrinsic clearance, \((\text{CL}_{\text{int,app}})\) and scaled apparent intrinsic clearance \((\text{CL}_{\text{int,app,sc}})\) were calculated for each metabolic pathway using the following equations:

\[ \text{CL}_{\text{int,app}} = \frac{V_{\text{max}}}{K_M} \]

\[ \text{CL}_{\text{int,app,sc}} = \text{CL}_{\text{int,app}} \times \frac{45 \text{ mg protein}}{g \text{ liver}} \times \frac{21 \text{ g liver}}{kg \text{ body weight}} \]
Unbound CL\textsubscript{int} values were calculated by dividing the respective CL\textsubscript{int} by the unbound liver microsomal free fraction (f\textsubscript{u,mic}) determined in HLM using equilibrium dialysis. When necessary, the measured f\textsubscript{u,mic} was scaled to reflect the respective microsomal protein concentration according to the method of Austin et al (2002). The fractional contribution by an individual metabolic pathway (f\textsubscript{CL(HLM)}) in HLM to the total in vitro clearance of PF-07321332 was calculated as:

\[ f_{CL(HLM)} = \frac{CL_{int,app,x}}{CL_{int,app,all}} \]

where, CL\textsubscript{int,app,x} is the intrinsic clearance for metabolite x, and CL\textsubscript{int,app,all} is the sum of in vitro CL\textsubscript{int} values for all metabolites monitored.

**Multi Point Selective Inhibition of CYP3A4/5 Activity in HLM.** The effect of CYP3A-selective inhibition by ketoconazole on nirmatrelvir oxidative metabolite formation was assessed in HLM. Incubations (0.3 ml) were conducted in 100 mM potassium phosphate buffer (pH 7.4) containing MgCl\textsubscript{2} (3.3 mM), NADPH (1.2 mM), HLM (0.3 mg/ml), and nirmatrelvir (2.5 \textmu M) at 37 °C for 15 min in the absence or presence of varying concentrations of ketoconazole (0.001–10 \textmu M). Chemical inhibition experiments were conducted in triplicate. Sample bioanalysis for analyte quantitation was performed using LC-MS/MS as previously described in the enzyme kinetics protocol.

The maximum contribution of CYP3A to nirmatrelvir metabolism in HLM was determined by the percent activity remaining of each metabolite in the presence of a broad concentration range of ketoconazole (0.001–10 \textmu M). The percent activity remaining was obtained by normalizing concentration data to the averaged solvent controls. Curve fitting of the activity
versus inhibitor concentration data by nonlinear regression to a four-parameter inhibition model was conducted using GraphPad Prism:

\[ Y = Bottom + \frac{Top - Bottom}{1 + \left( \frac{10^{\log IC_{50}}}{10^X} \right)^{HillSlope}} \]

where bottom is the minimum activity, top is the maximal activity, \( IC_{50} \) is the inhibitor concentration at half maximal activity, \( X \) is the inhibitor concentration, and \( Y \) is percent of enzyme activity remaining. The maximal contribution by the CYP isoform was determined as the difference between the maximum and minimum percent activity remaining based on data fitting.

The fraction of nirmatrelvir metabolized (\( f_m \)) to a single metabolite \( x \) by a specific CYP isoform \( z \) (\( f_{mMx,CYP_z} \)) was calculated using the following equation:

\[ f_{mMx,CYP_z} = f_{INH} \times f_{CL} \]

where \( f_{INH} \) is the scaled fraction of metabolite (M) \( x \) inhibited by a CYP specific inhibitor \( z \) and \( f_{CL} \) is the fraction of nirmatrelvir clearance represented by metabolite \( x \) determined from enzyme kinetic experiments.

**Single Point Selective Inhibition of CYP3A4 vs CYP3A5 Activity in HLM.** Nirmatrelvir (2.5 \( \mu \)M) was incubated with HLM pooled from CYP3A5*1/*1 (extensive metabolizers) (Sekisui XenoTech, Kansas City, KS) in the presence of selective chemical inhibitors ketoconazole (1 \( \mu \)M) (CYP3A4/5) and CYP3cide (1 \( \mu \)M) (CYP3A4) for the determination of CYP3A4 and CYP3A5 isoform contribution to the metabolism of nirmatrelvir. Incubations (0.3 ml) were conducted in 100 mM potassium phosphate buffer (pH 7.4) containing MgCl\(_2\) (3.3 mM), NADPH (1.2 mM), 0.3 mg/mL HLM at 37 °C for 15 min in a heat block. Chemical inhibition studies were conducted in triplicate. Stock solutions of ketoconazole and CYP3cide were
prepared in 50/50 methanol/H₂O. The microsome mixtures containing inhibitor and NADPH were warmed for 5 min (keto) or 10 min (CYP3cide) prior to initiating the reaction by addition of nirmatrelvir. Solvent control incubations were performed in the absence of chemical inhibitors. Sample bioanalysis for analyte quantitation was performed using LC-MS/MS as previously described in the enzyme kinetics procedure. To discern the contributions of CYP3A4 and CYP3A5 isoforms to nirmatrelvir metabolism in HLMs, the differential effects of CYP3A and CYP3A4 selective chemical inhibitors on metabolite formation rate was calculated using the following formula:

$$\text{%Inhibition (unscaled)} = (1 - \frac{v_{\text{inh}}}{v_{\text{ctrl}}}) \times 100\%$$

where $v_{\text{inh}}$ is the formation rate in the presence of inhibitor and $v_{\text{ctrl}}$ is the formation rate in the solvent control incubation. Determination of CYP3A5 contribution to each metabolic pathway was calculated as the difference in % inhibition by ketoconazole (CYP3A4/5) versus CYP3cide (CYP3A4) in HLM 3A5 *1/*1. Statistical analyses were conducted using GraphPad v. 8.02 to determine the statistical significance of inhibitor effect on metabolite formation rate versus minus inhibitor solvent control, and between the effects of ketoconazole versus CYP3cide, using a one-way ANOVA analysis with a Bonferonni’s Test for multiple comparisons. Statistical significance was set at $\alpha = 0.01$.

Results

nirmatrelvir (molecular weight = 499.53) is a moderately lipophilic (LogP = 1.68) neutral compound, which demonstrated low passive permeability ($P_{\text{app}}$) of $1.76 \times 10^{-6}$ cm/s in the low efflux Madin-Darby canine kidney (MDCKII-LE) cell assay (Di et al., 2011). In Caco-2 cell
monolayers, nirmatrelvir (0.11–231 μM) also exhibited low apical (A) to basolateral (B) permeability with values ranging from 0.66–1.19 x 10⁻⁶ cm/s (Supplemental Table 1). Co-incubation of nirmatrelvir (0.32 μM) with an efflux inhibitor cocktail comprised 10 μM Ko143 (breast cancer resistant protein (BCRP) inhibitor), 10 μM PSC833 (multidrug resistant gene 1 (MDR1) inhibitor), and 100 μM MK571 (multidrug resistance protein inhibitor) led to a considerable increase in the apparent permeability of nirmatrelvir from 0.80 ± 0.15 to 4.05 ± 0.26 cm/s (see Supplemental Table 1).

The substrate properties of nirmatrelvir towards human MDR1 and BCRP efflux transporters were examined in transporter-transfected MDCK cells by measuring the bidirectional permeability (P_{app} AB and P_{app} BA) (Supplemental Table 2). In MDCKI-MDR1 cells, nirmatrelvir (0.3–3.0 μM) demonstrated mean P_{app} (AB) and P_{app} (BA) values ranging from 0.12–0.21 (x 10⁻⁶ cm/s) and 9.94–10.3 (x 10⁻⁶ cm/s), respectively, resulting in efflux ratios of 48.4–83.7 across the concentration range. Inclusion of the MDR1 inhibitor PSC833 (5 μM) in the incubation mixtures led to a dramatic reduction (48–84 → 1.7–2.3) in nirmatrelvir efflux ratios. Under these experimental conditions, the prototypic MDR1 substrate quinidine (0.5 μM) demonstrated mean P_{app} (AB), P_{app} (BA), and efflux ratio values of 1.4 (x 10⁻⁶ cm/s), 78 (x 10⁻⁶ cm/s), and 58, respectively. Inclusion of the MDR1 inhibitor PSC833 (5 μM) decreased the efflux ratio of quinidine from ~ 58 to 1.0. The efflux ratio of nirmatrelvir (0.3–3.0 μM) in MDCKII-BCRP cells ranged from 1.4 to 1.5, suggesting that nirmatrelvir was not a substrate of human BCRP. Under these experimental conditions, the known BCRP substrate pitavastatin demonstrated mean P_{app} (AB) and P_{app} (BA) values of 0.4 (x 10⁻⁶ cm/s) and 11 (x 10⁻⁶ cm/s), respectively, which resulted in an efflux ratio of ~ 25. Inclusion of the selective BCRP inhibitor Ko143 (5 μM) led to a significant decrease of the pitavastatin efflux ratio from 25 to 0.2.
The equilibrium solubility of crystalline nirmatrelvir-MTBE co-solvate and anhydrous ‘form 1’ in unbuffered water was 7.21 mg/ml (pH 7.9) and 1.2 mg/ml (pH 7.0), respectively. The dissolution of crystalline nirmatrelvir-MTBE co-solvate in water was ~ 20-times faster than crystalline nirmatrelvir anhydrous ‘form 1’. The likelihood of a peptidase mediated hydrolytic cleavage across the peptide backbone in nirmatrelvir was examined in gastrointestinal fluids, which included SIF and SGF and intestinal fluid from healthy human volunteers (Smart et al., 2014; Wang et al., 2015). nirmatrelvir (1 μM) was stable (t_{1/2} > 240 min) towards hydrolytic cleavage in 2-hour incubations with SIF, SGF, and HIF.

**Plasma Protein Binding, Blood-to-Plasma Partitioning, and Non-Specific HLM Binding of Nirmatrelvir.** Nirmatrelvir (0.3–10 μM) demonstrated moderate and concentration-independent plasma protein binding in rat, monkey, and human with mean unbound plasma fractions (f_{u,p}) of 0.478, 0.434, and 0.310, respectively (Supplemental Table 3). Nirmatrelvir (0.3–10 μM) was stable in rat, monkey, and human plasma for ~ 6 h at 37 °C. The mean (± SD) blood-to-plasma ratios (BPRs) for nirmatrelvir (1 μM) in rat, monkey, and human were 0.83 ± 0.049, 0.68 ± 0.024, and 0.60 ± 0.024, respectively, suggesting that nirmatrelvir distributed into plasma preferentially over red blood cells. The mean (± SD) of unbound fraction of nirmatrelvir (2 μM) in HLM (1 mg/ml protein concentration) was 0.824 ± 0.017.

**Metabolic Stability Studies with Nirmatrelvir.** The metabolic stability of nirmatrelvir (1 μM) was examined in liver microsomes (fortified with NADPH) and cryopreserved hepatocytes from rat, monkey, and human using a substrate depletion assay format (Table 1). Nirmatrelvir did not demonstrate metabolic turnover in liver microsomes from animals and human when NADPH was excluded from the incubations. In the presence of NADPH, nirmatrelvir demonstrated low metabolic turnover (CL_{int,app} = 6.1 μl/min/mg) in rat liver microsomes, but underwent extensive
metabolism ($\text{CL}_{\text{int,app}} = 161 \, \mu l/min/mg$) in liver microsomes from monkey. Metabolic turnover in
NADPH-supplemented HLM was moderate ($\text{CL}_{\text{int,app}} = 28.8 \, \mu l/min/mg$, unbound $\text{CL}_{\text{int,app}} = 34.9$
$\mu l/min/mg$). In cryopreserved hepatocytes from rat, monkey, and human, nirmatrelvir
demonstrated low total $\text{CL}_{\text{int,app}}$ ($\mu l/min/10^6$ cells) of 4.64, 10.3, and 5.16, respectively. The total
$\text{CL}_{\text{int,app}}$ in liver microsomes and hepatocytes were scaled to yield the corresponding hepatic
clearance ($\text{CL}_{\text{hep}}$) values (Table 1) using the well-stirred model (Di et al., 2012).

**Metabolite Characterization.** Figures 2 and 3 depict HPLC-UV chromatogram of incubation
mixtures of nirmatrelvir (10 $\mu M$) in NADPH-supplemented liver microsomes and cryopreserved
hepatocytes from rats, monkeys, and humans, respectively. Elucidated structures of the
metabolites based on mass and $^1$H NMR spectral data are depicted in Figure 4. A total of 5
oxidative metabolites were observed in liver microsomes, to varying degrees, across rat, monkey,
and human. The metabolites were derived from mono-hydroxylation (metabolites M1–M4) and
dehydrogenation ($m/z$ 498). Although metabolism in hepatocytes was apparently slower than in
liver microsomes under the conditions examined, a similar metabolic profile was observed in the
two matrices. There were no human unique metabolites of nirmatrelvir; all metabolites observed
in HLM and human hepatocytes were also characterized in liver microsomes and hepatocytes
from rats and monkeys. The regiochemistry of oxidation was tentatively assigned based on
comparison of the mass spectral fragmentation data for the parent and its oxidized products.
Structures of metabolites M1–M4 were unambiguously identified via NMR characterization of
the biosynthesized samples obtained from scaled-up incubations of nirmatrelvir in NADPH-
fortified HLM.

**Nirmatrelvir.** A protonated molecular ion ($m/z^+$) of 500.2473 was observed for nirmatrelvir,
which is consistent with a molecular formula of $\text{C}_{23}\text{H}_{33}\text{N}_5\text{O}_4\text{F}_3$ (-1.23 ppm). Diagnostic fragment
ions in the collision-induced dissociation (CID) spectrum included \( m/z \) 319.1625 (cleavage of the acyl moiety on the 2-position of the [3.1.0]azabicyclic ring) and \( m/z \) 291.1813 (cleavage of the acyl moiety on the 3-position of the [3.1.0]azabicyclic ring), which yielded opposing portions of nirmatrelvir. Further fragmentation of \( m/z \) 319 yielded the [3.1.0]azabicyclic ring (\( m/z \) 110.0964) such that modifications of this portion of the molecule were readily observable in the mass spectra (see elucidation of M1 and M2 below).

The \(^1\text{H} \) NMR spectra of nirmatrelvir (Supplemental Figure 1) contains three amide resonances assigned to three hydrogens; H14: \( \delta \) 9.41 (d, coupling constant (\( J \)) = 8.1 Hz, 1H), H17: 9.02 (d, \( J \) = 8.4 Hz, 1H) and H23: 7.67 (s, 1H). Additionally, the \(^1\text{H} \) NMR spectra of nirmatrelvir contains fifteen aliphatic resonances assigned to twenty-nine hydrogens; H18: 4.98 (m, 1H), H13: 4.42 (d, \( J \) = 8.3 Hz, 1H), H6: 4.17 (s, 1H), H2”: 3.92 (dd, \( J \) = 10.0, 5.4 Hz, 1H), H2': 3.70 (d, \( J \) = 10.4 Hz, 1H), H22’: 3.15 (t, \( J \) = 8.9 Hz, 1H), H22”: 3.05 (q, \( J \) = 8.9 Hz, 1H), H20: 2.41 (m, 1H), H19”/21”: 2.12 (m, 2H), H19’/21’: 1.72 (m, 2H), H3: 1.58 (t, \( J \) =6.3 Hz, 1H), H5: 1.33 (d, \( J \) = 7.5 Hz, 1H), H9: 1.04 (s, 3H), H26/32/33: 0.99 (s, 9H) and H10: 0.86 (s, 3H).

**Metabolite M1 (PF-07329265).** Metabolite M1 (designated as PF-07329265) possessed a protonated molecular ion of \( m/z^+ \) 516.2435, consistent with a molecular formula of C\(_{23}\)H\(_{33}\)N\(_5\)O\(_5\)F\(_3\) (1.3 ppm), which was indicative of a monohydroxylation in nirmatrelvir. The dominant fragment ion (\( m/z \) 335.1585) in the CID spectrum of PF-07329265 suggested that the N-((S)-1-cyano-2-((S)-2-oxopyrrolidin 3-yl)ethyl)formyl portion in nirmatrelvir was not modified (Supplemental Figure 2). In the high energy C-trap dissociation (HCD) spectrum, the fragment ion of \( m/z \) 126.0917 is diagnostic of the region of hydroxylation being the 6,6-dimethyl-3-azabicyclo[3.1.0]hexane fused ring.
The $^1$H NMR spectrum (Supplemental Figure 3) of biosynthesized PF-07329265 revealed that only the resonances of the methyl hydrogens (H9 and H10) of the 6,6-dimethyl-3-azabicyclo[3.1.0]hexane fused ring had changed significantly from those observed in the $^1$H NMR spectrum of nirmatrelvir. Notably, the $^1$H methyl resonance observed at $\delta$ 1.04 in nirmatrelvir was absent in isolated PF-07329265, and a new resonance was observed at $\delta$ 3.24 which integrated to two hydrogens. In the $^1$H-$^{13}$C multiplicity edited heteronuclear single quantum coherence (HSQC) data of the isolate, this new resonance correlated to a carbon with a chemical shift of $\delta$ 67.9 (Supplemental Figure 4, panels B and C). The integration, $^1$H and $^{13}$C chemical shifts of this new resonance are all consistent with the oxidation of one of the geminal-dimethyl groups on the azabicyclohexane moiety.

To determine the configuration of this stereocenter, a series of ROE experiments were performed (Supplemental Figure 4, panels D-F). Irradiation of $^1$H methyl resonance at $\delta$ 0.86 led to an enhancement of the resonance assigned as the H6 methine and the H2’ methylene. Additionally, when the new resonance at $\delta$ 3.24 was irradiated, only the remaining methyl of the dimethylazabicyclohexane motif was significantly enhanced. With the stereo configuration of carbon 6 of the dimethylazabicyclohexane fixed in the $S$ orientation, an energy minimized three dimensional structure of PF-07329265 (Supplemental Figure 5) placed the remaining methyl at 2.6 Å from the C2-position methine (carbon 6 using Advanced Chemistry Development laboratory nomenclature). In this model, the new methylene is 3.8 Å from the C2-position methine. Based on this data, the structure of M1 (PF-07329265) is assigned as $(1R,2S,5S,6S)$-N-\{(1S)-1-cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl\}-6- (hydroxymethyl)-6-methyl-3-[3-methyl-N-(trifluoroacetyl)-L-valyl]-3-azabicyclo[3.1.0]hexane 2-carboxamide.
Metabolite M2. Metabolite M2 (PF-07329266) possessed a protonated molecular ion of $m/z^+ 516.2441$, which was consistent with a molecular formula of $C_{23}H_{33}N_5O_5F_3$ (2.5 ppm) and also suggested a monohydroxylation in nirmatrelvir. The CID spectrum possessed the same fragment ions as M1 (PF-07329265) but with differing abundances suggesting that, like M1, the hydroxylation has occurred on the 6,6-dimethyl-3-azabicyclo[3.1.0]hexane fused ring (Supplemental Figure 6). The $^1H$ NMR spectrum of biosynthesized PF-07329266 indicated that only the methyl protons in the dimethylazabicyclohexane ring had changed significantly from the ones observed in similarly acquired spectra of nirmatrelvir (Supplemental Figure 7). The $^1H$ methyl resonance observed at $\delta 0.86$ was absent in the isolated material with a new resonance observed at $\delta 3.26$ which integrated to two protons. This data established that M2 (PF-07329266) is a diastereomer of M1 (PF-07329265) at the C6-position whose structure is assigned as $(1R,2S,5S,6R)-N-\{1S)-1-cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl\}-6-(hydroxymethyl)-6\text{-methyl-3-[3-methyl-N-(trifluoroacetyl)-L-valyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide}.$

Metabolite M3. Metabolite M3 (PF-07329267) possessed a protonated molecular ion of $m/z^+ 516.2268$, consistent with a molecular formula of $C_{23}H_{33}N_5O_5F_3$ (3.8 ppm) and a monohydroxylated nirmatrelvir metabolite. The CID spectra of $m/z 516$ did not provide meaningful fragment ions for structural assignment, however the HCD spectrum afforded $m/z 237.0856$ and 110.0968 as additional diagnostic fragment ions (Supplemental Figure 8). The latter ion indicates that the azabicyclohexane ring is unmodified. The former, $m/z 237.0856$, is consistent with azabicyclohexane ring scission yielding an ion possessing the trifluoroacetyl and tert-butyl groups with a dehydrated hydroxyl group. This creates the possibilities of hydroxylation of the amide nitrogen of the trifluoroacetamide, the tert-butyl group, or the carbon connecting these two. The $^1H$ spectrum of biosynthesized PF-07329267 (Supplemental Figure 9)
indicated a change in the proton resonances of the tert-butyl methyl relative to those observed in similarly acquired spectra for nirmatrelvir. The tert-butyl resonance in nirmatrelvir displayed a chemical shift at δ 0.99, which integrated to 9 hydrogen atoms. In the $^1$H spectrum of PF-07329267, the resonance was now at δ 0.89 and integrated to a total of 6 hydrogen atoms. Additionally, the HSQC spectral data revealed the presence of a new inequivalent methylene pair of resonances at δ 3.14/3.53 corresponding to a carbon with a chemical shift of 68.5 (Supplemental Figure 10). Based on these data the structure of M3 (PF-07329267) is assigned as (1R,2S,5S)-N-[(1S)-1-cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[4-hydroxy-3-methyl-N-(trifluoroacetyl)-L-valyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide.

**Metabolite M4.** Metabolite M4 (PF-07329268) was the dominant oxidative metabolite of nirmatrelvir in liver microsomes and hepatocytes from animals and human. PF-07329268 comprised two closely eluting interconverting diastereomers, and possessed a protonated molecular ion of $m/z$ 516.2436, which was consistent with a molecular formula of C$_{23}$H$_{33}$N$_5$O$_5$F$_3$ (1.5 ppm), and indicated yet another monohydroxylation in nirmatrelvir. PF-07329268 underwent facile in-source dehydration to $m/z$ 498.2327, and subsequent fragmentation was conducted on this major ion (Supplemental Figure 11). The CID spectra of $m/z$ 498 yielded a major ion of $m/z$ 319.1636, which indicates that the azabicyclo[3.1.0]hexanyl-dimethylloxobutane-trifluoroacetamide portion was unmodified. The facile loss of water and the equilibrating diastereomers suggest, but do not prove, that the site of hydroxylation is on the C5-position of the pyrrolidinone ring. The $^1$H spectrum of biosynthesized PF-07329268 (Supplemental Figure 12) revealed that the resonances of the C22 methylene were absent. Moreover, the $^1$H-13C HSQC spectra of the isolated metabolite revealed the presence of a new $^1$H methine resonance at δ 5.01, which correlated with a carbon atom at a chemical shift of δ 77.3
(Supplemental Figure 13). Based on these data, M4 (PF-07329268) was assigned as (1\text{R},2\text{S},5\text{S})-N-((1\text{S}) 1-cyano-2-[(3\text{R})-5-hydroxy-2-oxopyrrolidin-3-yl]ethyl}-6,6-dimethyl-3-[3-methyl-N-(trifluoroacetyl)-L-valyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide.

**Pharmacologic Activity of M4 (PF-07329268).** M4 (PF-07329268), the major in vitro oxidative metabolite of nirmatrelvir in animals and human, was active against recombinant SARS-CoV-2 3CL\text{pro} with a \(K_i\) value (3 nM) comparable to the one noted with nirmatrelvir (Owen et al., 2021). Moreover, PF-07329268 also repressed SARS-CoV-2 replication in epithelial Vero E6 cells (Boras et al., 2021). However, the corresponding \(EC_{50}\) for PF-07329268 in the cellular antiviral assay was relatively weaker than the one observed with the parent compound (PF-07329268 \(EC_{50} = 690\) nM, PF-07321332 \(EC_{50} = 74.5\) nM).

**Metabolite \textit{m/z} 498.** A protonated molecular ion at \(m/z^+\ 498.2332\) was observed, consistent with a molecular formula of \(C_{23}H_{31}N_{5}O_{4}F_{3}\ (1.9\) ppm). While this might be considered an in-source dehydration product of a hydroxylated metabolite, the presence of a sodiated ion at \(m/z\ 520.2151\ (C_{23}H_{30}N_{5}O_{4}F_{3}Na; 1.7\) ppm) precludes this possibility and suggests that it is a dehydrogenated metabolite of nirmatrelvir. The fragments in CID and HCD spectra for this metabolite (Supplemental Figure 14) are identical to those generated from fragmentation of the in-source dehydrated ion of \(m/z\ 498\) of metabolite M4, therefore it is likely that the dehydrogenation occurred on the pyrrolidinone ring. However, the exact site of the dehydrogenation was not clear.

HPLC-UV profile of nirmatrelvir (10 \(\mu\)M) incubations with a panel of major human recombinant enzymes revealed that only CYP3A4 (and 3A5) (see Figure 2) were able to recapitulate the metabolic pathways of nirmatrelvir observed in NADPH-supplemented HLM and human hepatocytes.
Enzyme Kinetics and \( f_{\text{CL}} \) Determination for Nirmatrelvir Metabolism in HLM. Enzyme kinetic parameters and unbound \( \text{CL}_{\text{int,app}} \) values for the formation of M1 (PF-07329265), M2 (PF-07329266), M3 (PF-07329267), and M4 (PF-07329268) in NADPH-supplemented HLM incubations with nirmatrelvir (0.02–200 \( \mu \)M) are depicted in Table 2, and associated kinetic data are presented graphically in Figure 5 and corresponding Eadie-Hofstee plots are presented in Supplemental Figure 15. Visual inspection of the Eadie-Hofstee plots suggested typical hyperbolic Michaelis-Menten kinetics for M1 and M4. Metabolite formation rates for M1 and M4 were fitted to a Michaelis-Menten model with resulting \( K_M \) and \( V_{\text{max}} \) values of 28.0 \( \mu \)M and 17.2 pmol/min/mg, and 25.5 \( \mu \)M and 381 pmol/min/mg, respectively. Formation rates for M2 were best fitted to a 2-enzyme non-saturable model where the low affinity kinetic parameters could not be accurately defined with the nirmatrelvir concentration range tested, and therefore the secondary rate (\( \text{CL}_{\text{int}(2)} \)) of the low affinity enzyme(s) was estimated by linear approximation. The \( K_M \), \( V_{\text{max}} \), and \( \text{CL}_{\text{int}(2)} \) estimates for M2 were 24.0 \( \mu \)M, 9.79 pmol/min/mg, and 0.00508 \( \mu l/min/mg \), respectively. M3 formation rate data were best fit to an allosteric sigmoidal model where the estimated \( K_{\text{half}}, \ V_{\text{max}}, \) and Hill values were 31.0 \( \mu \)M, 15.2 pmol/min/mg, and 0.959, respectively. Based on these kinetic parameter estimates, the unbound \( \text{CL}_{\text{int,app}} \) values for the formation of M1, M2, M3, and M4 were 0.654, 0.439, 0.522, and 15.9 \( \mu l/min/mg \), yielding a summed unbound \( \text{CL}_{\text{int,app}} \) of 17.5 \( \mu L/min/mg \) for the oxidative metabolism of nirmatrelvir to M1–M4. Based on the output of the metabolite identification work, the in vitro hepatic metabolism of nirmatrelvir can be assumed to be predominantly oxidative in HLM, with an overall \( f_{m,CYP} \) of 1. The fractions of nirmatrelvir clearance (\( f_{\text{CL}} \)) representing formation of M1, M2, M3, and M4 were 0.037, 0.025, 0.030, and 0.91, respectively.
Contribution of CYP3A4/5 in the Oxidative Metabolism of Nirmatrelvir. Contributions by CYP3A4/5 to the metabolism of nirmatrelvir were examined using a multiple concentration CYP selective chemical inhibitor study design in HLM (Table 3 and Figure 6). For all four metabolites, inhibition curves were best fit to a four-parameter inhibition model. In the presence of ketoconazole (0.001–10 µM) the formation of M1, M2, M3, and M4 was inhibited 95%, 96%, 98%, and 99%, respectively.

The relative contribution of CYP3A4 and CYP3A5 towards the oxidative metabolism of nirmatrelvir to M1–M4 was examined in HLM from genotyped individuals expressing high (CYP3A5*1/*1) CYP3A5 enzyme in the presence or absence of non-selective CYP3A4/5 and selective CYP3A4 inhibitors, ketoconazole and CYP3cide (Tseng et al., 2014), respectively (Table 4). Differences between the inhibitory effects of CYP3cide and ketoconazole for the formation of M1 (3.7%), M3 (3.0%), and M4 (12%) were not statistically significant using a one-way ANOVA with Bonferroni’s multiple comparison test (α = 0.01). Assessment of the differential inhibitory effects on M2 formation rates was not possible due to concentrations below the limit of quantitation in the presence of both inhibitors. Because M2 represents a minor metabolic pathway (fCL = 0.025), further studies were not conducted. In summary, no significant CYP3A5 contribution is expected to the overall metabolism of nirmatrelvir in CYP3A5*1/*1 individuals.

Assigned CYP fm values for the oxidative metabolites of nirmatrelvir in HLM, based on the combined results of nirmatrelvir enzyme kinetics and chemical inhibition studies, are presented in Table 3. After normalizing the contribution of CYP3A to the fCL for each metabolic pathway, the fraction of M1, M2, M3, and M4 generated by CYP3A4 (fm,CYP3A) was 0.036, 0.024, 0.029, and 0.90, respectively, with a combined CYP3A4 fm of 0.99 and fm related to other unassigned
CYPs of 0.01. Collectively, these results indicated that the major enzyme involved in the metabolism ($f_m = 0.99$) of nirmatrelvir in HLM is CYP3A4.

**Biliary Excretion of Unchanged Nirmatrelvir in SCHH.** The potential for hepatobiliary excretion of nirmatrelvir in unchanged form was examined in SCHH. Following a 10 min incubation in SCHH, the corresponding $\text{CL}_{\text{biliary,int,app}}$ for nirmatrelvir (0.5 μM) in SCHH was 2.1 μl/min/mg, which was scaled using the methodology described by Kimoto et al (2017) to yield a predicted human $\text{CL}_{\text{bile}}$ of 2.7 ml/min/kg. The corresponding biliary excretion index of nirmatrelvir was ~ 43%. In comparison, positive control rosuvastatin (0.5 μM) (Kimoto et al., 2017) demonstrated $\text{CL}_{\text{biliary,int,app}}$ and biliary excretion index of 5.0 μl/min/mg and 52%, respectively.

**PK of Nirmatrelvir in Animals.** The PK parameters of nirmatrelvir after single iv and po dose administration in rats and monkeys is shown in Table 5 and mean plasma concentrations versus time profile are shown in Supplemental Figure 16. Nirmatrelvir (1 mg/kg) demonstrated moderate plasma clearance ($\text{CL}_p$) in rats (27.2 ml/min/kg) and monkeys (17.1 mL/min/kg) with low (0.33 L/kg – monkeys) to moderate (1.8 L/kg – rats) $V_{dss}$ values in the two species. The terminal $t_{1/2}$ ranged from 0.79 h (monkeys) to 5.1 h (rats). The percentage of unchanged nirmatrelvir excreted over a 24-h period in rat and monkey urine was 17% and 7.0%, which yielded $\text{CL}_{\text{renal}}$ values of 4.5 and 1.3 ml/min/kg, respectively. The unbound renal blood clearance of nirmatrelvir in rats and monkeys, estimated using the protocol described by Dong et al (2016), was 12 ml/min/kg and 4.0 ml/min/kg, respectively, and was within the range of the glomerular filtration rate in the respective species (rats = 8.7 ml/min/kg and monkeys = 4.0 ml/min/kg) (Lin, 1995), suggesting little-to-no active tubular secretion. Consistent with these observations were the findings on the lack of substrate properties of nirmatrelvir towards a broad array of the major
human renal transporters, including the organic anion transporters (OAT)1 and 3, multidrug and toxin extrusion protein (MATE)1 and 2K, organic cation transporter 2, and organic anion transporting polypeptide (OATP)4C1 (Pfizer data on file). Following iv administration of nirmatrelvir (1 mg/kg) to bile-duct cannulated rats, 8.9 ± 4.7% of the administered dose was observed in rat bile in unchanged parent form, which translated to a CL\textsubscript{biliary} of 2.4 ml/min/kg. Comparison of the predicted CL\textsubscript{hep} values using NADPH-supplemented liver microsomes and hepatocytes from rats and monkeys (Table 1) with the observed CL\textsubscript{plasma} (after subtracting for CL\textsubscript{renal} and CL\textsubscript{bile}) revealed a reasonably good (within ~ 2.5–5.0-fold in rats and within 2-fold in monkeys) in vitro-in vivo correlation for clearance.

Oral PK studies were conducted with two crystalline versions of nirmatrelvir; nirmatrelvir-MTBE co-solvate and anhydrous nirmatrelvir ‘Form 1’. Following po administration of nirmatrelvir (10 mg/kg) as MTBE co-solvate, nirmatrelvir was rapidly absorbed (T\textsubscript{max} = 0.25–1.5 h) in rats and monkeys, with corresponding oral bioavailability (F) values of 50% and 8.5%, respectively. The corresponding fraction of the nirmatrelvir po dose absorbed (F\textsubscript{a} x F\textsubscript{g}) in rats and monkeys was 82% and 18%, respectively. The relatively lower F of nirmatrelvir in monkeys is likely due to CYP-mediated oxidative metabolism along the gastrointestinal tract, since nirmatrelvir demonstrated a facile metabolic decline (t\textsubscript{1/2} = 20.5 min, CL\textsubscript{int.app} = 33.8 µl/min/mg) in monkey intestinal microsomes in a NADPH-dependent fashion. This hypothesis is further substantiated by the observation that unchanged nirmatrelvir constituted ~ 4% of the administered dose in feces collected from monkeys after the po dosing (data not shown). As such, nirmatrelvir did not demonstrate any metabolic turnover (t\textsubscript{1/2} > 240 min, CL\textsubscript{int.app} < 2.89 µl/min/mg) in rat and human intestinal microsomes in the presence of NADPH. Anhydrous nirmatrelvir ‘Form 1’ orally administered (10 mg/kg) to rats also demonstrated rapid absorption
(T\textsubscript{max} = 0.25 h), albeit with a lower F and lower F\textsubscript{a} x F\textsubscript{g} values of 34 ± 19% and 56%, when compared with the anhydrous nirmatrelvir-MTBE co-solvate.

**Interactions with Human CYP Enzymes. CYP Inhibition.** Nirmatrelvir exhibited no reversible (IC\textsubscript{50} > 100 µM) inhibition of CYP1A2 (phenacetin-O-dealkylation), CYP2B6 (bupropion hydroxylation), CYP2C8 (amodiaquine N-dealkylation), CYP2C9 (diclofenac-4′-hydroxylation), CYP2C19 (S-mephenytoin-4′-hydroxylation), and CYP2D6 (dextromethorphan-O-demethylation) catalytic activities in NADPH-supplemented HLM. Nirmatrelvir, however, demonstrated weak reversible inhibition of CYP3A4/5 catalyzed testosterone-6β-hydroxylase, midazolam-1′-hydroxylase, and nifedipine oxidase activities with IC\textsubscript{50} values of 58.3 µM, 106 µM, and 45.1 µM, respectively (Supplemental Table 4). An IC\textsubscript{50} shift of 2.13x (midazolam-1′-hydroxylase) and 1.73x (testosterone-6β-hydroxylase) following a 30-min preincubation of nirmatrelvir in NADPH-supplemented HLM (Supplemental Table 4), suggested that nirmatrelvir is a reversible and time-dependent inhibitor of CYP3A enzyme activities. In the IC\textsubscript{50} shift assay, nirmatrelvir was devoid of time-dependent inhibition of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2D6 enzyme activities. Under the present experimental conditions, known CYP isozyme-specific reversible (and time-dependent) positive control inhibitors (Walsky and Obach, 2004) demonstrated potent reversible and time-dependent inhibition of CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A activity, respectively, in NADPH-supplemented HLM (Pfizer data on file).

**Kinetics for the Time-dependent inhibition (TDI) of CYP3A by Nirmatrelvir.** Nirmatrelvir demonstrated time (1–40 min)- and concentration (0.1–100 µM)-dependent inhibition of the midazolam-1′-hydroxylase and testosterone-6β-hydroxylase activities in NADPH-supplemented HLM (Figure 7). Nirmatrelvir (100 µM) did not cause TDI of CYP3A activity in HLM.
incubations in the absence of NADPH (see Figure 7). The corresponding kinetic constants:

maximal rate of inactivation ($k_{inact}$) and inactivator concentration required to achieve 50% $k_{inact}$ ($K_I$) for TDI of the CYP3A catalyzed midazolam-1'-hydroxylase (and testosterone 6β-hydroxylase) activity by nirmatrelvir were 0.0142 min$^{-1}$ (0.0165 min$^{-1}$) and 15.5 μM (13.9 μM), respectively. The ratio of $k_{inact}/K_I$ for the two marker substrates midazolam and testosterone was 0.916 ml/min/μmol and 1.23 ml/min/μmol, respectively (Supplemental Table 5). The rates of CYP3A inactivation in HLM with positive control verapamil (Walsky and Obach, 2004) were within historical results (Pfizer data on file).

Metabolic Intermediate (MI) Complex Formation. The potential for quasi-irreversible inhibition of CYP3A4 by nirmatrelvir via the formation of a metabolic intermediate complex (Orr et al., 2012) was examined in incubations of nirmatrelvir with NADPH-supplemented recombinant human CYP3A4 supersomes by monitoring the absorption spectra for the signature MI Soret absorbance at $\lambda \approx 455$ nm (Franklin, 1974). As shown in Supplementary Figure 17, the absorbance at 455 nm did not increase following addition of NADPH to incubations of CYP3A4 supersomes and nirmatrelvir. In contrast, an expected increase in absorbance at 455 nm was observed in incubations of CYP3A4 supersomes/NADPH with the positive control troleandomycin, which is known to inactivate CYP3A4 via MI complex formation (Mayhew et al., 2000).

CYP Induction. The potential for induction of CYP3A4 messenger RNA (mRNA) and enzyme (midazolam-1'-hydroxylase) activity was examined in 4 lots (BXM, BNA, FOS, and HH1144) of cryopreserved human hepatocytes treated with nirmatrelvir (0.01-200 μM) for 48 hours. Nirmatrelvir demonstrated moderate induction of CYP3A mRNA levels and in a dose-dependent fashion in all four donor hepatocytes. Induction of CYP3A mediated midazolam-1’-
hydroxylase activity was seen in 3 out of the 4 lots. The maximal fold induction ($\text{Ind}_{\text{max}}$) and inducer concentration required to achieve 50% $\text{Ind}_{\text{max}}$ ($\text{EC}_{50}$) values for fold increases in CYP3A mRNA levels and midazolam-1’-hydroxylase activity in the four individual human hepatocytes with nirmatrelvir are shown in Supplemental Table 6. A cytotoxicity assay using Promega’s CellTiter 96® aqueous nonradioactive cell proliferation assay kit (Promega, WI) showed no reduction in hepatocyte cell viability after treatment with nirmatrelvir at the tested concentrations. Under these experimental conditions, treatment of the four donor human hepatocyte lots with a single concentration (10 $\mu$M) of the positive control rifampicin led to the expected increases in CYP3A4 mRNA and catalytic activity. Moreover, rifampin demonstrated ~2–3-fold greater increase in CYP3A mRNA and ~2–5-fold greater increase in enzyme activity relative to the effects observed with nirmatrelvir at the higher end of its tested concentration range (50–200 $\mu$M).

**Interactions with Human Drug Transporters.** Inhibitory effects of nirmatrelvir against the major human intestinal, hepatobiliary and renal drug transporters were examined using human embryonic kidney (HEK)293 cells or vesicles (Supplemental Table 7). Nirmatrelvir inhibited N-methylquinidine transport in human MDR1 expressing HEK293 vesicles with an $\text{IC}_{50}$ value of 71 $\mu$M. Inhibition of rosuvastatin transport ($\text{IC}_{50} = 44$ $\mu$M) in OATP1B1 expressing HEK293 cells was also observed with nirmatrelvir. Relatively weaker inhibition ($\text{IC}_{50}$’s > 100 $\mu$M) by nirmatrelvir was noted against OATP1B3, the organic cation or anion transporters (OCT1, OCT2, OAT1 and OAT3), MATE1, and MATE2K.

**Discussion**

A major objective of our discovery campaign was to identify a compound(s) that had improved preclinical oral absorption relative to the intravenous agent PF-00835231 (oral F and $F_a \times F_g =$
1.4% and 3.3% (rat), < 0.05% and < 1% (monkey)), while retaining the antiviral potency towards SARS-CoV-2 (Owen et al., 2021). The low oral absorption of PF-00835231 was largely attributed to a high hydrogen bond donor (HBD) count (Veber et al., 2002), which resulted in poor passive permeability (MDCK II $P_{app} < 0.27 \times 10^{-6}$ cm/s) across cells (Boras et al., 2021). Reduction in HBD count (PF-00835231 HBD = 5 $\rightarrow$ PF-07321332 (nirmatrelvir) HBD = 3) was achieved through the M$^{\text{pro}}$ co-crystal structure-guided replacements of the P1’ ($\alpha$-hydroxymethyl ketone $\rightarrow$ nitrile), P2 (leucine $\rightarrow$ 6,6-dimethyl-3-azabicyclo[3.1.0]hexane as a cyclic leucine mimic), and P3 (methoxyindole $\rightarrow$ trifluoroacetamide capping group) structural elements to yield a broad coronavirus inhibitor PF-07321332 (nirmatrelvir), which retained the potent inhibitory attributes of PF-00835231 towards SARS-CoV-2 3CL$^{\text{pro}}$, and possessed antiviral activity in cells, and in a mouse-adapted SARS-CoV-2 model of COVID-19 (Owen et al., 2021). Nirmatrelvir also demonstrated pan-human coronavirus activity through inhibition of 3CL$^{\text{pro}}$ enzymes associated with alpha- and beta-coronaviruses capable of infecting humans (Owen et al., 2021). Lack of inhibitory effects towards several mammalian protease enzymes established the selectivity of nirmatrelvir as a coronavirus inhibitor.

A reduced HBD count also led to considerable improvements in oral absorption. Although nirmatrelvir demonstrated relatively low passive permeability, and was a MDR1 substrate in vitro, oral administration of two crystalline forms (MTBE co-solvate and anhydrous ‘form 1’) of nirmatrelvir (10 mg/kg) to rats led to reasonable oral F (34-50%), with the MTBE co-solvate demonstrating better absorption relative to the anhydrous ‘form 1’. The superior oral absorption profile of the MTBE co-solvate presumably occurred because of its higher thermodynamic aqueous solubility and faster dissolution rate as compared to ‘form 1’. The relatively poor bioavailability of MTBE co-solvate in monkeys was attributed to oxidative metabolism by CYP.
enzymes along the gastrointestinal tract, based on the monkey intestinal microsomal stability data. Nirmatrelvir was resistant to CYP oxidations in intestinal microsomal preparations from rats and human, and moreover, complete resistance towards peptide backbone hydrolysis via the putative action of digestive enzymes was also noted in gastrointestinal fluids.

The low oral F (8.5%) of nirmatrelvir in monkeys did not deter toxicological investigations in this species (Owen et al., 2021). Daily dosing of nirmatrelvir-MTBE co-solvate (60–600 mg/kg) in 2-week regulatory toxicity studies led to robust increases in C_{max} and AUC (Supplemental Table 8), most likely due to saturation and/or autoinhibition of first-pass oxidative metabolism in monkeys with increasing doses. Corresponding unbound systemic concentration (C_{max} and AUC) margins at the highest dose (600 mg/kg) were > 200-fold over the measured unbound EC_{90} (181 nM) in the dNHBE assay. Rats orally administered with nirmatrelvir (40–1000 mg/kg) yielded unbound concentrations of ~ 273-fold (C_{max}) and 65-fold (AUC) over the dNHBE unbound EC_{90} at the 1000 mg/kg dose (Owen et al., 2021). nirmatrelvir was virtually devoid of any adverse findings at the highest doses tested in animals. It is noteworthy to point out that the SARS-CoV-2 dNHBE EC_{90} was also targeted as a minimally efficacious clinical concentration based on the observation that trough/C_{min} concentrations over cellular antiviral EC_{90} values are required for clinical efficacy with protease inhibitors and other antivirals (Food and Drug Administration, 2006; Reddy et al., 2012). Improvements in oral absorption also permitted a thorough evaluation of the antiviral activity of nirmatrelvir in a mouse model of COVID-19. Twice daily administration of nirmatrelvir (300 and 1000 mg/kg) in mice for 4 days protected the animals from weight loss and led to statistically significant reductions in viral load in the lungs of the infected animals with corresponding trough plasma concentrations maintained at ~0.9-fold and 4.0-fold over the dNHBE EC_{90} (Owen et al., 2021).
The anticipated clearance mechanisms of nirmatrelvir in humans include oxidative metabolism, almost exclusively by CYP3A4, and some degree of renal and biliary excretion. In NADPH-supplemented HLM and human hepatocytes, nirmatrelvir demonstrated moderate metabolic turnover, to yield CL\textsubscript{int,app} values of 28.8 $\mu$l/min/mg and 5.16 $\mu$l/min/10$^6$ cells, respectively, which were scaled to afford estimated CL\textsubscript{hep} values of 6.3 and 3.2 ml/min/kg, respectively. Metabolic pathways of nirmatrelvir in liver microsomes and hepatocytes from animals and human, comprising exclusively of CYP oxidation products, were virtually identical. The major metabolite M4, derived from pyrrolidinone ring oxidation in nirmatrelvir, demonstrated potent inhibition of recombinant SARS-CoV-2 3CL\textsuperscript{pro} activity, but was relatively weaker as an antiviral agent in cells, potentially due to an impaired permeability, which was driven by the introduction of an additional HBD (OH group). Reaction phenotyping revealed that the selective CYP3A4/5 inhibitor ketoconazole inhibited the formation of the oxidative metabolites M1–M4 in HLM by 95–99%, with minimal contribution from CYP3A5 in pooled HLM with high CYP3A5$^{*}1^{*/*}1$ activity. Overall, this in vitro exercise, which established a preponderance of CYP3A4 mediated metabolism of nirmatrelvir, also created a potential opportunity to enhance the therapeutic concentrations of nirmatrelvir in humans following concomitant administration with the CYP3A4 inhibitor ritonavir. Ritonavir is used as a PK booster of several marketed protease inhibitors such as darunavir and lopinavir that are predominantly metabolized by CYP3A4 (Cvetkovic and Goa, 2003; Mckeage et al., 2009; Larson et al., 2014).

Examination of inhibitory effects of nirmatrelvir towards major human CYP enzymes revealed inhibitory (reversible and time-dependent) and induction effects only against CYP3A. The mechanistic basis for the CYP3A TDI by nirmatrelvir is presently unclear, and rules out a
quasi-irreversible inhibitory pathway via MI complex formation as previously demonstrated with some peptidomimetics (Ernest et al., 2005). Projection of PK interactions through mechanistic modeling (Food and Drug Administration, 2020) of the predicted human PK parameters and the in vitro CYP3A inhibition/induction data suggested that nirmatrelvir is likely to increase the AUC of drugs metabolized by CYP3A by 3.0–4.0-fold (Pfizer data on file). Moreover, regulatory guidance (European Medicines Agency, 2012; Food and Drug Administration, 2020) for assessing DDIs arising from inhibition of drug transporters also suggested the possibility of interactions between nirmatrelvir and drugs that are substrates for MDR1 and OATP1B1, based on the weak in vitro inhibitory effects noted for these transporters. Overall, the disposition attributes, particularly the dominance of CYP3A-catalyzed oxidative metabolism over non-metabolic elimination pathways, and the CYP3A4 inhibitory/inducing effects of nirmatrelvir is largely reminiscent of the profiles seen with marketed peptidomimetics, particularly ones (e.g. indinavir, darunavir, and lopinavir) used to treat acquired immunodeficiency syndrome (Lin et al., 1996; Kumar et al., 2004; Vermeir et al., 2009).

First-in-human pharmacokinetics of the crystalline anhydrous ‘form 1’ of nirmatrelvir administered as a single agent (150 mg) and in combination with ritonavir (nirmatrelvir 250 mg + ritonavir at -12 h, 0 h, and 12 h) (www.ClinicalTrials.gov NCT04756531) revealed a considerable enhancement in systemic concentrations of nirmatrelvir in the presence of ritonavir (Owen et al., 2021), which was consistent with the predominant role of CYP3A4 in nirmatrelvir metabolic clearance. The plasma concentrations of nirmatrelvir in the presence of ritonavir at 12 h post-dose were considerably greater than the SARS-CoV-2 antiviral EC$_{90}$ value in dNHBE cells, which bolstered our confidence in attaining antiviral activity against pan coronaviruses (Owen et al., 2021). Detailed data from the safety, tolerability, and clinical pharmacokinetics of
nirmatrelvir and nirmatrelvir/ritonavir combination across single- and multiple-ascending doses have been recently submitted for publication (Singh et al., 2022). In a recent phase 2/3 trial (Study NCT04960202 on ClinicalTrials.gov), the combination of nirmatrelvir/ritonavir (Paxlovid™) demonstrated robust efficacy at reducing hospitalization and death in high-risk COVID-19 patients by 89% (within three days of symptom onset) and 88% (within five days of symptom onset) compared to placebo. Paxlovid™ has been recently granted emergency use authorization by multiple regulatory agencies across the globe including the United States Food and Drug Administration for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older), who are at high risk for progression to severe COVID-19, including hospitalization or death.

Acknowledgments

We would like to acknowledge the significant number of Pfizer colleagues who have contributed to the COVID-19 oral protease program, since its inception in March 2020. In particular, we acknowledge Elaine Tseng and Gabrielle Gualtieri for the conduct of the CYP inhibition studies, Matthew Cerny for the conduct of the CYP metabolic intermediate complex experiment, Angela Doran for assistance with CYP phenotyping and blood partitioning studies, Nathaniel Johnson for executing CYP induction studies, Yi-An Bi, Sarah Lazzaro, Sumathy Mathialagan, Sangwoo Ryu, Mark West, and Emi Yamaguchi for the conduct of in vitro transporter assays, Marcus Ewing and Susan Ewing for solubility, dissolution, and formulation studies, Amanda Plante and Chad Limanni for experimental assistance with preclinical pharmacokinetics studies, Fran Clark for bioanalytical measurements, and Qingyi Yang for constructing the SARS-CoV-2/nirmatrelvir co-crystal structure graphic. Finally, we would like to thank Charlotte Allerton for a critical review of the manuscript.
Authorship Contributions

Participated in research design: Kalgutkar, Boras, Di, Obach, Singh

Conducted experiments: Dantonio, Eng, Kadar, Kimoto, Novak, Obach, Walker

Contributed new reagents or analytic tools: Obach, Walker

Performed data analysis: Boras, Dantonio, Di, Lin, Eng, Kadar, Kimoto, Novak, Obach, Patel, Walker, Singh

Wrote or contributed to the writing of the manuscript: Kalgutkar, Boras, Dantonio, Di, Eng, Kadar, Kimoto, Obach, Patel, Walker, Singh

Footnotes

‡ ASK, BB, AD, LD, HE, EPK, EK, JJN, RSO, NCP, GSW, and RSPS are employees of Pfizer and some of the authors are shareholders in Pfizer Inc. JJN was an employee of Pfizer Inc. during part of this study.

‡ Present address: Praxis Precision Medicines; Cambridge, MA 02142.

Funding

This work received no external funding.
References


Figure Legends

**Figure 1.** Chemical structures of PF-00835231 (intravenous COVID-19 clinical candidate) and PF-07321332 (nirmatrelvir, oral COVID-19 clinical candidate) and binding mode of PF-07321332 in the 3CL\textsuperscript{pro} active site of SARS-CoV-2. PF-07321332 inhibits 3CL\textsuperscript{pro} activity via a reversible covalent bond formation between its nitrile group and an active site Cys145 residue.

**Figure 2.** HPLC-UV chromatograms of NADPH-supplemented liver microsomal incubations and human recombinant CYP3A4 with PF-07321332 (nirmatrelvir, 10 \(\mu\)M). Drug-related peaks are denoted with P for parent drug and M for metabolites. All unmarked peaks represent non-drug-related interferences present in control incubations (not shown). Metabolite M2 in the human liver microsomal incubation is a shoulder on the larger interfering peak. Metabolite M4 is present as two closely eluting peaks representing the two interconverting diastereomers.

**Figure 3.** HPLC-UV chromatograms of cryopreserved primary hepatocyte incubation extracts for nirmatrelvir (10 \(\mu\)M). Drug-related peaks are denoted with P for parent drug and M for metabolites. All unmarked peaks represent non-drug-related interferences present in control incubations (not shown). Metabolite M4 is present as two closely eluting peaks representing the two interconverting diastereomers.

**Figure 4.** Metabolites of PF-07321332 (nirmatrelvir) in liver microsomes and hepatocytes from rat, monkey, and human.

**Figure 5.** Substrate saturation plots for the formation of the primary PF-07321332 (nirmatrelvir) metabolites PF-07329265 (M1), PF-07329266 (M2), PF-07329267 (M3), and PF-07329268 (M4) following incubation of PF-07321332 (0.02–200 \(\mu\)M) with HLM (0.3 mg/ml).
**Figure 6.** Inhibition of the formation of M1–M4 metabolites of PF-07321332 (nirmatrelvir, 2.5 μM) in HLM in the presence of the selective CYP3A inhibitor ketoconazole (0.001–10 μM). Panel A, PF-07329265 (M1); Panel B, PF-07329266 (M2); Panel C, PF-07329267 (M3); and Panel D, PF-07329268 (M4)

**Figure 7.** Time-, concentration-, and NADPH-dependent inhibition of CYP3A4/5 catalyzed midazolam-1’-hydroxylase (panels A and C) and testosterone-6β-hydroxylase (panels B and D) activities in HLM by PF-07321332 (nirmatrelvir). 100-NADPH = PF-07321332 (100 μM) incubations in HLM in the absence of NADPH co-factor. Panels C and D depict enzyme kinetics parameter fit ($k_{obs}$ versus PF-07321332 concentrations) for midazolam and testosterone hydroxylation, respectively.
### Tables

**TABLE 1**

*Metabolic stability of nirmatrelvir in liver microsomes and hepatocytes*

<table>
<thead>
<tr>
<th>Reagent</th>
<th>Co-factor</th>
<th>$t_{1/2}$ (min)</th>
<th>$\text{CL}_{\text{int,app}}$ ($\mu\text{l/min/mg or } \mu\text{l/min}/10^6 \text{ cells}$)</th>
<th>$\text{CL}_{\text{hep}}$ (ml/min/kg)</th>
<th>Observed $\text{CL}_{\text{plasma}}$ (ml/min/kg)$^c$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liver Microsomes$^a$</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rat</td>
<td>NADPH</td>
<td>114</td>
<td>6.08</td>
<td>5.8</td>
<td>22.7</td>
</tr>
<tr>
<td>Monkey</td>
<td>NADPH</td>
<td>4.31</td>
<td>161</td>
<td>25</td>
<td>15.8</td>
</tr>
<tr>
<td>Human</td>
<td>NADPH</td>
<td>24.1</td>
<td>28.8</td>
<td>6.3</td>
<td>---</td>
</tr>
<tr>
<td>Hepatocytes$^b$</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rat</td>
<td>NA</td>
<td>300</td>
<td>4.64</td>
<td>11</td>
<td>22.7</td>
</tr>
<tr>
<td>Monkey</td>
<td>NA</td>
<td>135</td>
<td>10.3</td>
<td>13</td>
<td>15.8</td>
</tr>
<tr>
<td>Human</td>
<td>NA</td>
<td>280</td>
<td>5.16</td>
<td>3.2</td>
<td>---</td>
</tr>
</tbody>
</table>

$^a$Metabolic stability of nirmatrelvir (0.1 or 1.0 $\mu$M) was examined in NADPH-supplemented liver microsomes from rat, monkey and human (1 mg/ml protein concentration) for 60–80 min at 37 °C. Liver microsomal stability studies were conducted in triplicate.

$^b$Metabolic stability of nirmatrelvir (1.0 $\mu$M) was examined in hepatocytes from rat, monkey and human (0.5 x10$^6$ cells/ml) for 240 min at 37 °C. Hepatocyte stability studies were done in duplicate.

$^c$Depicted in vivo $\text{CL}_{\text{plasma}}$ is after subtracting $\text{CL}_{\text{renal}}$ in the respective species.

Stability data governed by half-life ($t_{1/2}$) was scaled to apparent intrinsic clearance ($\text{CL}_{\text{int,app}}$) and hepatic plasma clearance ($\text{CL}_{\text{hep}}$) using the well-stirred model (see Supplemental Information).

NA = not applicable.
TABLE 2

Enzyme kinetics and fractional clearance determination for the metabolism of nirmatrelvir in human liver microsomes

<table>
<thead>
<tr>
<th></th>
<th>PF-07329265 (M1)</th>
<th>PF-07329266 (M2)</th>
<th>PF-07329267 (M3)</th>
<th>PF-07329268 (M4)</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Model</td>
<td>MM</td>
<td>2-enzyme MM (^b)</td>
<td>2-enzyme MM (^c)</td>
<td>AS</td>
<td>MM</td>
</tr>
<tr>
<td>(K_M) (µM)</td>
<td>28.0</td>
<td>24.0</td>
<td>--</td>
<td>31.0</td>
<td>25.5</td>
</tr>
<tr>
<td>(V_{max})</td>
<td>17.2</td>
<td>9.79</td>
<td>--</td>
<td>15.2</td>
<td>381</td>
</tr>
<tr>
<td>(h)</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>0.959</td>
<td>--</td>
</tr>
<tr>
<td>(CL_{int,app,u}) (^a)</td>
<td>0.654</td>
<td>0.434</td>
<td>0.00541</td>
<td>0.522</td>
<td>15.9</td>
</tr>
<tr>
<td>(f_{CL})</td>
<td>0.037</td>
<td>0.025</td>
<td>0.030</td>
<td>0.030</td>
<td>0.91</td>
</tr>
<tr>
<td>(CL_{int,app,u}) (^a)</td>
<td>0.91</td>
<td>1.00</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

AS = Allosteric sigmoidal; \(f_{CL}\) = fractional clearance; \(h\) = Hill slope; \(K_M\) = substrate concentration at half-maximal velocity; MM = Michaelis-Menten; \(V_{max}\) = maximum velocity.

Data represent the mean of two replicates.

\(^a\)Protein adjusted microsomal free fraction = 0.940 for 0.3 mg/ml incubation protein concentration. \(^b\)Highest affinity parameters reported. \(^c\)Low affinity linear approximation, \(CL_{int,app,u}\) reported.

\(f_{CL}\) was calculated from:

\[
f_{CL(\text{HLM})} = \frac{CL_{int,app,x}}{CL_{int,app,all}}
\]
### TABLE 3

**Assignment of fractional CYP contribution to the metabolism of nirmatrelvir in pooled HLM**

<table>
<thead>
<tr>
<th>Metabolic Pathway</th>
<th>Fraction of Clearance (f(_{CL}))(^a)</th>
<th>Fraction Inhibited(^b)</th>
<th>Fraction Metabolized (f(_m))(^d)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>CYP3A4</td>
</tr>
<tr>
<td>PF-07329265 (M1)</td>
<td>0.037</td>
<td>0.95</td>
<td>0.048</td>
</tr>
<tr>
<td>PF-07329266 (M2)</td>
<td>0.025</td>
<td>0.96</td>
<td>0.043</td>
</tr>
<tr>
<td>PF-07329267 (M3)</td>
<td>0.030</td>
<td>0.98</td>
<td>0.020</td>
</tr>
<tr>
<td>PF-07329268 (M4)</td>
<td>0.91</td>
<td>0.99</td>
<td>0.0084</td>
</tr>
<tr>
<td>Total</td>
<td>1.0</td>
<td>0.99</td>
<td>0.01</td>
</tr>
</tbody>
</table>

Data represent mean of three replicates. Nirmatrelvir (2.5 \(\mu\)M) was incubated in pooled HLM in the absence/presence of ketoconazole (0.001–10 \(\mu\)M).

\(^a\)\(f_{CL}\) = fractional clearance (see Table 2).

\(^b\)The maximum contribution was determined by the percent activity remaining compared with a no inhibitor solvent control. Maximum percent inhibition was calculated using the equation:

\[ Y = \text{Bottom} + \frac{\text{Top} - \text{Bottom}}{1 + \left(\frac{10^{\text{LogIC}_{50}}}{10^X}\right)^{\text{HillSlope}}} \]

\(^c\)Other CYP isoforms unaccounted for, by inhibition with ketoconazole.

\(^d\)\(f_m\) = fraction metabolized calculated from:

\[ f_{mMxCYPz} = \frac{\% \text{ inhibition}}{100} \times f_{CL} \]
TABLE 4

Inhibition of nirmatrelvir (2.5 μM) metabolism in pooled HLM with high (CYP3A5*1/*1) CYP3A5 activity

<table>
<thead>
<tr>
<th>HLM Lot</th>
<th>Inhibitor</th>
<th>CYP</th>
<th>PF-07329265 (M1)</th>
<th>PF-07329266 (M2)</th>
<th>PF-07329267 (M3)</th>
<th>PF-07329268 (M4)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>% Inhibition</td>
<td>% Inhibition</td>
<td>% Inhibition</td>
<td>% Inhibition</td>
</tr>
<tr>
<td>HLM 3A5*1/*1</td>
<td>Control</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Ketoconazole (1 μM)</td>
<td>3A4/5</td>
<td>98</td>
<td>&gt;94</td>
<td>98</td>
<td>97</td>
</tr>
<tr>
<td></td>
<td>CYP3cide (1 μM)</td>
<td>3A4</td>
<td>94</td>
<td>&gt;94</td>
<td>95</td>
<td>85</td>
</tr>
<tr>
<td>% contribution</td>
<td>CYP3A5</td>
<td>NS (3.7)</td>
<td>ND</td>
<td>NS (3.0)</td>
<td>NS (12)</td>
<td></td>
</tr>
</tbody>
</table>

ND = not determined; NS = not significant; Data represent the mean of triplicate experiments. Significance based on one-way ANOVA analysis with Bonferroni’s multiple comparison test, p <0.01.
In cases where analyte concentrations were undetectable, the velocity was calculated using the LLOQ value.

^p-value was 0.0294.
TABLE 5
Pharmacokinetics of nirmatrelvir in rats and monkeys

<table>
<thead>
<tr>
<th>Species</th>
<th>Dose (mg/kg)</th>
<th>C&lt;sub&gt;max&lt;/sub&gt; (ng/ml)</th>
<th>T&lt;sub&gt;max&lt;/sub&gt; (h)</th>
<th>AUC&lt;sub&gt;0-∞&lt;/sub&gt; (ng·h/ml)</th>
<th>CL&lt;sub&gt;p&lt;/sub&gt; (ml/min/kg)</th>
<th>Vd&lt;sub&gt;ss&lt;/sub&gt; (l/kg)</th>
<th>t&lt;sub&gt;1/2&lt;/sub&gt; (h)</th>
<th>Oral F (%)</th>
<th>F&lt;sub&gt;a&lt;/sub&gt; x F&lt;sub&gt;g&lt;/sub&gt; (%)&lt;sup&gt;d&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>1.0 (iv)</td>
<td>----</td>
<td>----</td>
<td>632 (523, 741)</td>
<td>27.2 (22.5, 31.9)</td>
<td>1.8 (1.4, 2.2)</td>
<td>5.1 (3.3, 7.0)</td>
<td>----</td>
<td>----</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>1290 (851, 1730)</td>
<td>1.5 (1.0, 2.0)</td>
<td>3190 (1890, 4480)</td>
<td>----</td>
<td>----</td>
<td>4.0 (2.9, 5.1)</td>
<td>50 (30, 71)</td>
<td>82</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>1450 ± 373</td>
<td>0.25 ± 0.0</td>
<td>2170 ± 1180</td>
<td>----</td>
<td>----</td>
<td>2.8 ± 1.4</td>
<td>34 ± 19</td>
<td>56</td>
</tr>
<tr>
<td>Monkey</td>
<td>1.0 (iv)</td>
<td>----</td>
<td>----</td>
<td>977 (965, 988)</td>
<td>17.1 (16.9, 17.3)</td>
<td>0.33 (0.31, 0.34)</td>
<td>0.79 (0.74, 0.83)</td>
<td>----</td>
<td>----</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>1450 (1050, 1850)</td>
<td>0.25 (0.25, 0.25)</td>
<td>831 (747, 914)</td>
<td>----</td>
<td>----</td>
<td>----</td>
<td>8.5 (7.7, 9.4)</td>
<td>18</td>
</tr>
</tbody>
</table>

<sup>a</sup>Pharmacokinetic parameters were calculated from plasma concentration–time data and are reported as mean (± S.D. for n=3 and individual values for n=2). All pharmacokinetics were conducted in males of each species (Wistar-Han rats and cynomolgus monkey). Intravenous (iv) doses for nirmatrelvir were administered as a solution in 10% DMSO/30% PEG400/60% deionized water.
(rats) or 5% (v/v) PEG400/95% (v/v) of 23% 2-hydroxypropyl-β-cyclodextrin in aqueous sodium phosphate buffer pH = 6.0 (monkeys).

Oral (po) pharmacokinetics studies were conducted in the fed state. Oral rat pharmacokinetics studies were conducted with crystalline nirmatrelvir anhydrous MTBE solvate or anhydrous 'Form 1'. Nirmatrelvir-MTBE solvate and anhydrous 'form 1' forms were formulated as solutions in 10% (v/v) ethanol/10% (v/v) Capmul MCM/35% (v/v) PEG400/45% (v/v) Tween80 and 2% (v/v) Tween80/98% of 0.5% (w/v) methyl cellulose in deionized water, respectively. Rats received 8 ml/kg oral of 1% Hydroxypropyl cellulose in deionized water immediately prior to the nirmatrelvir-MTBE solvate po dose. For po pharmacokinetics assessments in monkeys, crystalline MTBE solvate form of nirmatrelvir was administered as a solution in 2% (v/v) Tween80/98% of 0.5% (w/v) methyl cellulose in deionized water.

\[ \text{AUC}_{0-t} \]

Fraction of the po dose absorbed estimated from CL\(_{\text{plasma}}\) after subtracting CL\(_{\text{renal}}\). CL\(_{\text{plasma}}\) was converted into CL\(_{\text{blood}}\) by dividing CL\(_{\text{plasma}}\) by the blood-to-plasma ratio in the respective species. Q is the hepatic blood flow (70 ml/min/kg (rats) and 44 ml/min/kg (monkeys)).

\[
F_a \times F_g = \frac{F}{1 - \frac{\text{CL}_{\text{blood}}}{Q}}
\]

Nirmatrelvir was dosed as the anhydrous MTBE solvate.

Nirmatrelvir was dosed as the anhydrous 'form 1'.
Figure 1

PF-00835231

Nirmatrelvir (PF-07321332)
Figure 2

Female rat

Male rat

Monkey

Human

Recombinant CYP3A4

Absorbance (A) at 300 nm

Time (min)

6.0 6.5 7.0 7.5 8.0 8.5 9.0 9.5 10.0
Figure 3
Figure 4

\[ \text{m/z 498} \rightarrow \text{Nirmatrelvir (PF-07321332)} \rightarrow \text{M1 (PF-07329265)} \]

\[ \text{M4 (PF-07329268)} \rightarrow \text{M3 (PF-07329267)} \rightarrow \text{M2 (PF-07329266)} \]
Figure 5

- **PF-07329265 (M1)**
- **PF-07329266 (M2)**
- **PF-07329267 (M3)**
- **PF-07329268 (M4)**
Figure 7

Graphs showing enzyme activity over time and concentration relationships.

A: Enzyme activity over time with different concentrations.
B: Enzyme activity over time with different concentrations.
C: Kinetic constant (kcat) vs. concentration of substrate.
D: Kinetic constant (kcat) vs. concentration of substrate.
Disposition Of PF-07321332 (Nirmatrelvir), an Orally Bioavailable Inhibitor of SARS-CoV2 Main Protease, across Animals and Humans

Heather Eng¹, Alyssa L. Dantonio¹, Eugene P. Kadar¹, R. Scott Obach¹, Li Di¹, Jian Lin¹, Nandini C. Patel², Britton Boras¹, Gregory S. Walker¹, Jonathan J. Novak¹, Emi Kimoto¹, Ravi Shankar Singh², and Amit S. Kalgutkar²

Affiliations:
¹Pfizer Worldwide Research, Development & Medical; Groton, CT 06340, USA
²Pfizer Worldwide Research, Development & Medical; Cambridge, MA 02139, USA
³Pfizer Worldwide Research, Development & Medical; La Jolla, CA 92121, USA

Journal Title Drug Metabolism and Disposition

Supplemental Information
Abbreviations
Materials and Methods
References
Supplemental Figures
Supplemental Tables
Abbreviations:

P_{app}, apparent permeability; MDCKII-LE, low efflux Madin-Darby canine kidney cells; HBSS, Hanks balanced salt solution; BCRP, breast cancer resistant protein; MDR1, multidrug resistant gene 1; LC-MS/MS, liquid chromatography tandem mass spectrometry; f_{u,p}, unbound fraction in plasma; HLM, human liver microsomes; f_{u,mic}, unbound fraction in human liver microsomes; BPR, blood to plasma ratio; R_b, blood to plasma partitioning; NADPH, β-nicotinamide adenine dinucleotide phosphate, reduced form; CYP, cytochrome P450; t_{1/2}, half-life; CL_{int,app}, apparent intrinsic clearance; CL_{int,scaled}, scaled intrinsic clearance; CL_{hep}, hepatic clearance; iv, intravenous; po, oral; MTBE, methyl-tert-butyl ether; AUC, area under the plasma concentration-time curve; CL_p, plasma clearance; V_{dss}, steady state distribution volume; F, oral bioavailability; F_a x F_g, fraction of the oral dose absorbed; Q, hepatic blood flow; CL_{blood}, blood clearance; DF, dilution factor; CL_{renal}, renal clearance; CL_{biliary}, biliary clearance; IC_{50}, half-maximal inhibitory concentration; k_{inact}, maximal rate of inactivation; K_i, inactivator concentration at k_{inact}; mRNA, messenger RNA; Ind_{max}, maximal fold induction; EC_{50}, inducer concentration that produces half Ind_{max}; HEK, human embryonic kidney cells; OAT, organic anion transporter; OCT, organic cation transporter; MATE, multidrug and toxin extrusion protein; OATP, organic anion transporting polypeptide.

Materials and Methods.

Passive Permeability Studies. Apparent permeability (P_{app}) of PF-07321332 was measured in Caco-2 (ATCC, Manassas, Manassas, VA) and in low efflux Madin-Darby canine kidney (MDCKII-LE) cell lines in triplicate with a modification to previously reported methodology (Di et al., 2011; Varma et al., 2012). For the MDCKII-LE assay, the modification included addition of 0.4% bovine serum albumin to the receiver compartment to minimize nonspecific binding, and thus maximize recovery of the analyte from the wells upon permeation across the cell monolayers. Briefly, MDCKII-LE cells were seeded onto the apical chambers of Millicell 96-well Transwell Plate (MilliporeSigma, Atlanta, GA) with 2.64 × 10^4 cells/well (0.1 ml of 2.64 × 10^5 cells/ml). Cells were incubated for 4 days at 37 °C, 5% CO_2, 90% relative humidity. On the assay day, PF-07321332 and control compounds (atenolol, nadolol, cyclosporin A, and metoprolol) were tested at 6 µM.
Caco-2 cells were seeded at 7.15 x 10^3 cells/well in 96-well transwell plates, and cultured in Dulbecco’s modified eagle’s medium-high glucose supplemented with 20% fetal bovine serum, 1% non-essential amino acids, 1% glutamax, 1% sodium pyruvate, and 0.6% gentamicin for 21 days. For donor solutions, final assay concentrations of PF-07321332 in the presence or absence of inhibitor cocktail were prepared using Hanks balanced transport buffer (HBSS) supplemented with 20 mM 4-(2-hydroxyethyl) piperazine-1-ethanesulfonic acid and 25 mM glucose. Receiver solutions contained 0.4% bovine serum albumin, with or without inhibitor cocktail. Inhibitor cocktail was made up of 10 µM Ko143 (BCRP inhibition), 10 µM PSC833 (MDR1 inhibition), and 100 µM MK571 (multi-drug resistance protein inhibition). Apical-to-basolateral (A-B) transport assay was started by the addition of donor and receiver solutions to the apical and basolateral compartments, respectively. The plates were then incubated for 1.5 hours at 37 °C. The transport assay was stopped by separating the apical plate from the basolateral plate. Samples were collected from the receiver and donor compartments for analysis of PF-07321332 and internal standard by liquid chromatography tandem mass spectrometry (LC-MS/MS). Data for Caco-2 assays were analyzed using Analyst version 1.6.3 (Sciex, Framingham, MA) and the resulting peak areas of PF-07321332 and internal standard were determined. The concentrations of test compound were calculated based on the results of the standard curves. A-B P_app values were calculated using Microsoft Excel 2007 software.

**In Vitro Transport Assays for BCRP and MDR1.** The human BCRP-transfected MDCKII cell line (BCRP-MDCKII) and the human MDR1-transfected MDCKI cell line (MDR1-MDCKI) and were licensed from MilliporeSigma (Atlanta, GA) and the National Institutes of Health (Rockville, MD), respectively. Detailed procedures for the transwell assay have been used as described previously (Feng et al., 2019). In brief, BCRP-MDCKII cells were seeded at a cell density of 2.5 x 10^4 cells/well in complete minimum essential medium α containing 10% fetal bovine serum with supplements (1% GlutaMAX™, 1% penicillin-streptomycin and 1% non-essential amino acids) on Millicell-96 Cell Culture Insert Plates, and incubated (37 °C, 5% CO₂, 90% relative humidity) for 5 days. MDR1-MDCKI cells were seeded at a cell density of 3.4 x 10^4 cells/well in complete Dulbecco’s modified Eagle’s medium high glucose containing 10% fetal bovine serum with supplements (1% GlutaMAX™, 1% penicillin-streptomycin and 1% sodium pyruvate) on Millicell-96 Cell Culture Insert Plates, and incubated (37 °C, 5% CO₂, 90% relative humidity) for 4 days. All transwell assays were performed with transport buffer (HBSS...
with 0.139 g/l calcium chloride, 25 mM D-glucose, 20 mM 4-(2-hydroxyethyl) piperazine-1-ethanesulfonic acid, and 0.102 g/l magnesium chloride) at pH 7.4. Transport assays were performed by adding PF-07321332 (0.3, 1, and 3 µM) and positive controls (0.5 µM of pitavastatin for BCRP and 0.5 µM of quinidine for MDR1) in transport buffer to donor wells and measuring appearance in receiver wells after a 1.5 h incubation at 37 °C. Samples were collected from the receiver and donor compartments for analysis by LC-MS/MS. The following equations were used to calculate \( P_{\text{app}} \) values and MDR1 or BCRP efflux ratio.

\[
P_{\text{app}} = \frac{1}{A \times C_0} \frac{dx}{dt}
\]

\[
\text{Efflux ratio} = \frac{P_{\text{app,BA}}}{P_{\text{app,AB}}}
\]

Where, \( A \) is the surface area of the transwell insert, \( C_0 \) is the initial concentration of a compound applied to the donor chamber, \( t \) is incubation time, \( x \) is the amount of a compound in the receiver compartment, and \( dx/dt \) is the flux of the compound across the cell monolayer.

**Plasma Protein Binding.** Plasma protein binding was determined using a 96-well equilibrium dialysis method (Banker et al., 2003). On the day of each incubation, fresh blood in K2EDTA was collected from male Wistar-Hannover rats (\( n=5 \), pooled), male Cynomolgus monkeys (\( n=2 \), pooled), and humans (\( n=1 \) male and \( n=1 \) female, pooled). The blood was centrifuged (10 min, 2500 x g) to harvest plasma. Plasma was spiked with a final concentration of 0.3, 1, 3, or 10 µM of PF-07321332 (final organic 1% DMSO). Fraction unbound in plasma (\( f_{u,p} \)) was determined by equilibrium dialysis using an HTD 96 device assembled with 12-14k molecular weight cutoff membranes (HTDialysis, LLC, Gales Ferry, CT). Dialysis chambers were loaded with 150 µl plasma and 150 µl phosphate buffered saline in the donor and receiver chambers, respectively. The dialysis plate was sealed with a gas-permeable membrane and stored in a 37 °C water-jacketed incubator maintained at 75% relative humidity and 5% CO\(_2\), on a 100 rpm plate shaker. After a 6-hour incubation, samples were matrix-matched and quenched by protein precipitation, followed by analysis of PF-07321332 by LC-MS/MS. A set of satellite samples was included to measure stability after a 6-hour incubation. Incubations were conducted with 12 replicates per concentration. The unbound plasma fraction of PF-07321332 was calculated by dividing the
analyte concentration in the buffer sample by the concentration in the donor sample, corrected for any dilution factors. All incubations had >70% analyte recovery and >70% stability in 6 h.

**Human Liver Microsomal Binding.** Unbound fraction of PF-07321332 in human liver microsomes (HLM) \( (f_{u,\text{mic}}) \) was determined in quadruplicate using 96-well equilibrium dialysis. HLM were thawed and diluted with 0.1 M potassium phosphate buffer (pH 7.4) to a final protein concentration of 1 mg/ml. PF-07321332 (final concentration = 2 \( \mu \text{M} \)) was added to the diluted microsomal solution (final organic 1% DMSO). Dialysis chambers were loaded with 150 \( \mu \text{l} \) HLM and 150 \( \mu \text{l} \) 0.1 M potassium phosphate buffer (pH 7.4) in the donor and receiver chambers, respectively. The remainder of the study was conducted using the methods described for plasma protein binding. HLM binding was scaled to desired protein concentration using the following (Austin et al, 2002), where \( f_{u_1} \) is the measured fraction unbound at a first microsomal concentration \( (C_1) \) and \( f_{u_2} \) is the calculated fraction unbound at a second microsomal concentration \( (C_2) \).

\[
\frac{1}{C_2} \left( \frac{1 - f_{u_1}}{f_{u_1}} \right) + 1
\]

**Blood to Plasma Ratio (BPR) Determination.** Blood to plasma partitioning \( (R_b) \) of PF-07321332 was determined in fresh rat, monkey, and human whole blood that was collected in \( \text{K}_2\text{EDTA} \). A 0.2 mM stock of PF-07321332 was prepared in 50% acetonitrile 50% water which was added to blood to yield a final concentration of 1 \( \mu \text{M} \) \( (n = 3, \text{final organic 0.25% acetonitrile}) \). An aliquot of blood was immediately removed for the stability determination. Samples were incubated on an orbital shaker in a humidified CO\(_2\) incubator for 60 min at 37 °C. Post incubation, a whole blood sample was collected. The remaining blood samples was centrifuged for 10 min at 2500 x g and a plasma sample was collected. Each sample was matrix matched with an equal volume of blank plasma or blood, followed by dilution with 1.25 volumes of water. The resulting sample (90 \( \mu \text{l} \)) was mixed with 200 \( \mu \text{l} \) of 50% acetonitrile 50% methanol containing an internal standard (5 ng/ml terfenadine). Supernatants were analyzed for PF-07321332 using LC-MS/MS. The BPR for PF-07321332 was calculated as the ratio of PF-07321332 concentration in the blood to concentration in the plasma. All incubations had >70% analyte recovery in 1 h.
**Microsomal Stability.** Liver. PF-07321332 (0.1 µM) was incubated in Wistar-Han rat (male and female), Cynomolgus monkey (male), and HLM (pool of 50 donors of mixed gender) purchased from Sekisui XenoTech (Kansas City, KS) (1 mg/ml) in potassium phosphate buffer (100 mM, pH 7.4) supplemented with MgCl₂ (3.3 mM) and β-Nicotinamide adenine dinucleotide phosphate, reduced form (NADPH) (1.3 mM) in a final volume of 400 µl. Stock solutions of PF-07321332 were prepared in acetonitrile (final concentration of acetonitrile in the incubations were ≤ 0.5%). Incubations were conducted at 37 °C in triplicate. Control incubations in the absence of NADPH were also conducted in parallel in duplicate. Periodic aliquots (40 µl) of the incubation mixture at 0, 5, 10, 15, 20, 30, 45 and 60 min were removed and quenched in acetonitrile (160 µl) containing diclofenac (25 ng/ml) as internal standard.

Intestine. PF-07321332 (1.0 µM) was incubated in phenylmethylsulfonyl fluoride-free (to preserve serine hydrolase enzymatic activity) rat (pool of 200, male Sprague-Dawley), (Sekisui XenoTech, Kansas City, KS), monkey (pool of 10, male cinomolagus) or human (pool of 9, male and female) (BioIVT, Baltimore, MD) intestinal microsomes (1 mg/ml) in potassium phosphate buffer (100 mM, pH 7.4) supplemented in MgCl₂ (3.3 mM) and NADPH (1.3 mM) in a final volume of 300 µl. The final acetonitrile concentrations in the incubations were ≤ 0.5%. Incubations were conducted at 37 °C in duplicate. Control experiments in the absence of NADPH were also conducted in parallel. Periodic aliquots (30 µl) of the incubation mixture at 0, 5, 15, 30, 60, 90 and 120 min were added to acetonitrile (120 µl) containing diclofenac (25 ng/ml) as internal standard.

Samples from the microsomal stability assays were vortexed, centrifuged (5 min, 2300 x g), and the supernatant was diluted with an equal volume of water. Samples were analyzed for depletion of PF-07321332 by LC-MS/MS. Analyst software (Sciex, Framingham, MA) was used to measure peak areas. Peak area ratios of analyte to internal standard were calculated. PF-07321332 depletion half-life (tₜ/₂) and apparent intrinsic clearance (CLₜₙₜ,ₜₚₚ) were calculated using E-WorkBook v10 (ID Business Solutions, Guildford, Surrey, UK). The natural log of peak area ratios versus time were fitted using linear regression, and the slope (k) was converted to tₜ/₂ values, where tₜ/₂ = -0.693/k. To estimate CLₜₙₜ,ₜₚₚ in liver microsomes, the tₜ/₂ for substrate depletion was scaled using the following equation (Obach et al., 1997).
The following equations were used to calculate scaled intrinsic clearance (CL_{int,scaled}) and hepatic blood clearance (CL_{hep,blood}) in liver microsomes from animals and human. The physiological constants for each species used were 40 g liver/kg body weight and Q of 70 ml/min/kg (rat), 32 g liver/kg body weight and Q of 44 ml/min/kg (monkey), and 21 g liver/kg body weight and Q of 20 ml/min/kg (human) (Davies and Morris, 1993). f_{umic} measured in HLM was used as a surrogate for all species (Zhang et al., 2010).

\[
CL_{int,app} = \frac{0.693 \cdot ml \text{ incubation}}{t_{1/2} \cdot \text{amount of protein in incubation}}
\]

Hepatocyte metabolic stability. Cryopreserved Wistar-Han rat (male, pool of 24 donors), cynomolgus monkey (male, pool of 3 donors), and human (pool of 13 donors of mixed gender) hepatocytes were purchased from BioIVT (Baltimore, MD). Hepatocytes were suspended at 0.5 x 10^6 viable cells/ml of Williams E media and prewarmed at 37 °C for 30 min. Incubations were initiated with the addition of PF-07321332 (final concentration = 1.0 µM, final DMSO concentration = 0.1%) and were conducted at 37 °C, 75% relative humidity, and 5% CO2. The reaction was stopped at 2, 4, 11, 45, 75, 120, or 240 min by the addition of acetonitrile (135 µl) containing a proprietary internal standard CP-628374 (0.177 µM). The samples were centrifuged at ~1900 x g for 5 min before LC-MS/MS analysis for the depletion of PF-07321332 in the incubations. The following equations were used to calculate CL_{int,app}, CL_{int,scaled}, and CL_{hep,blood} (Di et al., 2012). The physiological constants for each species used were 135 x 10^6 cells/g liver (rat), 120 x 10^6 cells/g liver (monkey), and 120 x 10^6 cells/g liver (human).

\[
Hepatocyte CL_{int,app} = \frac{0.693 \cdot ml \text{ incubation}}{t_{1/2} \cdot \text{million cells}}
\]

\[
Hepatocyte CL_{int,scaled} = Hepatocyte CL_{int,app} \cdot \frac{\text{million cells}}{g \text{ liver}} \cdot \frac{g \text{ liver}}{kg \text{ body weight}}
\]
\[ \text{CL}_{\text{hep, blood}} = \frac{Q \cdot f_{u,p} \cdot CL_{\text{int,scaled}}}{f_{u,mic}} \]

**LC-MS/MS Analysis of PF-07321332 from In Vitro Studies.** LC-MS/MS analysis was performed using a Sciex Triple Quad 6500 mass spectrometer (Sciex, Framingham, MA), equipped with an electrospray source and Agilent 1290 binary pump (Santa Clara, CA). Aqueous mobile phase (A) was comprised of 0.1% formic acid in water and organic mobile phase (B) consisted of 0.1% formic acid in acetonitrile. Samples (10 µl) from various in vitro incubations were injected onto a Kinetex XB-C18 (2.1 x 50 mm, 2.6 µm) (Phenomenex, Torrance, CA) column at room temperature with a flow rate of 0.5 ml/min. The gradient program typically began with 10% initial mobile phase B held for 0.2 min, followed by a linear gradient to 40% B over 2.3 min, then to 98% over 0.3 min, held at 98% B for 0.6 min followed by re-equilibration to initial conditions for 0.3 min. The mass spectrometer was operated in multiple reaction monitoring mode, in positive detection mode, with the mass transitions (Q1/Q3) and collision energies (CEs) of 500/110 and 30, respectively, for PF-07321332.

**Preclinical Pharmacokinetics Studies.** All activities involving animals were carried out in accordance with federal, state, local and institutional guidelines governing the use of laboratory animals in research in AAALAC accredited facilities and were reviewed and approved by Pfizer’s or Bioduro’s Institutional Animal Care and Use Committee.

**Rat Pharmacokinetics.** Rat pharmacokinetics studies were done at Pfizer (Groton, CT) or BioDuro Pharmaceutical Product Development Inc. (Shanghai, PRC); Jugular vein-cannulated male Wistar-Hannover rats were purchased from Charles River Laboratories, Inc. (Wilmington, MA) or Vital River (Beijing, China) and were typically 7-10 weeks of age at the time of dosing. During the pharmacokinetic studies all animals were housed individually. Access to food and water was provided ad libitum (i.e., subjects were dosed in the fed state). PF-07321332 was administered intravenously (iv) via the tail vein (n = 2 or 3) dosed as a solution (1 mg/kg, 1 ml/kg) or via oral (po) gavage as a solution or suspension (10 mg/kg, 10 ml/kg). Intravenous doses for PF-07321332 were administered as a solution in 10% DMSO/30% PEG400/60% deionized water. An iv dose of PF-07321332 (1 mg/kg) was also administered to bile duct-cannulated Sprague-Dawley rats (n=4), where plasma, bile, and urine samples were collected on
ice for up to 24 hours and stored at –20 °C until analysis. Serial blood samples from rat pharmacokinetics studies were collected before dosing and 0.033, 0.083, 0.25, 0.5, 1, 2, 4, 7, and 24 hours after dosing. Oral (po) rat pharmacokinetics studies were conducted with crystalline PF-07321332 methyl-tert-butyl ether (MTBE) solvate or anhydrous 'Form 1'. PF-07321332-MTBE solvate and anhydrous 'Form 1' forms were formulated as solutions in 10% (v/v) ethanol/10% (v/v) capmul MCM/35% (v/v) PEG400/45% (v/v) polysorbate and 2% (v/v) tween80/98% of 0.5% (w/v) methyl cellulose in deionized water, respectively. Rats received 8 ml/kg oral of 1% Hydroxypropyl cellulose in deionized water immediately prior to the PF-07321332-MTBE solvate po dose. Serial blood samples were collected via the jugular vein cannula at predetermined timepoints after dosing. Urine samples (0–7.0 and 7.0–24 h) were also collected after iv administration. At the completion of the study, animals were euthanized by overdose of inhaled anesthesia followed by exsanguination. Blood samples were collected into tubes containing K₂EDTA and stored on ice until centrifugation to obtain plasma, which was stored frozen at -20 °C or lower.

**Monkey Pharmacokinetics.** Monkey studies were conducted at Pfizer (Groton, CT). Male Cynomolgus monkeys were purchased from Covance (Princeton, NJ), Charles River Laboratories, Inc. (Wilmington, MA), or Envigo Global Services (Indianapolis, IN); subjects 3-8 years of age were used in pharmacokinetics studies. For each study (n=2), PF-07321332 was dosed iv by the saphenous vein (typically 1 mg/kg and 1 ml/kg) or via po gavage (typically 5–10 mg/kg, 5 ml/kg). For iv studies, PF-07321332 was administered as a solution in 5% (v/v) PEG400:95% (v/v) of 23% 2-hydroxypropyl-β-cyclodextrin in aqueous sodium phosphate buffer pH = 6.0. For po studies, crystalline MTBE solvate form of PF-07321332 was administered as a solution in 2% (v/v) tween80/98% of 0.5% (w/v) methyl cellulose in deionized water. Serial blood samples were collected via the femoral vein before dosing and at predefined time points post-dose. Urine samples (0–7.0 and 7.0–24 h) were also collected after iv administration. Blood samples were collected into K₂EDTA treated collection tubes and were stored on wet ice prior to being centrifuged to obtain plasma, which was stored frozen at -20 °C or lower.

**LC-MS/MS Analysis.** Bile and urine samples were diluted 1:9 in plasma. Plasma, bile or urine samples were processed using protein precipitation with 1:1 acetonitrile:methanol containing terfenadine (5 ng/ml) or buspirone (5 ng/ml) as an internal standard followed by quantitation
against a standard curve (0.1-2500 ng/ml) prepared in blank plasma. Briefly, a Waters ACQUITY ultra performance liquid chromatography system (Waters, Milford, MA) coupled to an Sciex 6500 triple quadrupole mass spectrometer equipped with an electrospray ionization source was used. Chromatographic separation was accomplished using a Waters Acquity UPLC BEH C18 column (1.7 µm, 2.1 × 50 mm) maintained at either room temperature or 45 °C. The mobile phase (2 solvents gradient) was optimized to achieve good separation between the analytes. Typically, solvent A constituted of 0.1% formic acid in water, and solvent B included 0.1% formic acid in acetonitrile. The gradient generally began at 5-30% B until about 1 min, followed by an increase to 95% B to 2.0 min and held for 0.5 min, then decreased to 5-30% B until ~2.6 min. MS/MS methods were the same as described for in vitro samples. Analyst v.1.7 software was used for peak integration and Watson v.7.5 (Thermo Scientific, Waltham, MA) was used for standard curve regression.

**Pharmacokinetic Analysis.** Pharmacokinetic parameters were calculated using noncompartmental analysis (Watson v.7.5). The area under the plasma concentration-time curve from t = 0 to infinity (AUC0-∞) was estimated using the linear trapezoidal rule. In some instances, pharmacokinetic calculations were generated using the linear log-linear trapezoidal rule and C0 was calculated using the equation:

\[ C_0 = \frac{Dose_{iv}}{V_b \times BPR} \]

where \( V_b \) is the blood volume (rat, 69.0 ml/min/kg; monkey, 62.3 ml/kg) and BPR is the blood to plasma ratio. Plasma clearance (\( CL_p \)) was calculated as:

\[ CL_p = \frac{Dose_{iv}}{AUC_{0-\infty}} \]

The terminal rate constant (\( k_{el} \)) was calculated by linear regression of the terminal phase of the log-linear concentration-time curve and the terminal elimination \( t_{1/2} \) was calculated as:

\[ t_{1/2} = \frac{0.693}{k_{el}} \]

Steady state distribution volume (\( Vd_{ss} \)) was determined by clearance multiplied by mean residence time. Oral bioavailability (\( F \)) was defined as:
\[ F = \frac{AUC_{po} \times Dose_{iv}}{AUC_{iv} \times Dose_{po}} \]

The fraction of the oral dose absorbed \((F_a \times F_g)\) was estimated using the equation (Kato et al., 2003):

\[ F_a \times F_g = \frac{F}{1 - \frac{CL_{blood}}{Q}} \]

A hepatic blood flow \((Q)\) of 70 ml/min/kg and 44 ml/min/kg was used for rats and monkeys, respectively (Davies and Morris, 1993). Blood clearance \((CL_{blood})\) was calculated by dividing \(CL_p\) by the blood-to-plasma ratio in the respective preclinical species.

The total amount of PF-07321332 excreted unchanged in urine or bile was calculated using the following equations and summing the amount in all collection intervals, where \(C_u\) and \(C_b\) are the measured urine and bile concentrations, respectively, \(DF\) is the dilution factor applied during bioanalysis, and \(V_u\) and \(V_b\) are the volumes of urine and bile collected during each time interval.

\[ Amount\ in\ Urine = C_u \times DF \times V_u \]
\[ Amount\ in\ Bile = C_b \times DF \times V_b \]

Renal clearance \((CL_{renal})\) and biliary clearance \((CL_{biliary})\) were calculated as:

\[ CL_{renal} = \frac{Amount\ in\ urine}{Amount\ dosed} \times CL_p \]
\[ CL_{biliary} = \frac{Amount\ in\ bile}{Amount\ dosed} \times CL_p \]

**CYP Inhibition Studies.** Reversible inhibition of major human CYP isoforms (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4/5) by PF-07321332 was evaluated via incubation of standard marker substrates (phenacetin (CYP1A2), bupropion (CYP2B6), amodiaquine (CYP2C8), diclofenac (CYP2C9), S-mephenytoin (CYP2C19), dextromethorphan (CYP2D6), testosterone (CYP3A4/5), midazolam (CYP3A4/5), and nifedipine (CYP3A4/5)) of human CYP isozymes with pooled HLM in the presence of NADPH (1.3 mM) in 100 mM potassium phosphate buffer, pH 7.4, containing 3.3 mM MgCl₂ at 37 °C open to air. The incubation volume was 0.2 ml. Microsomal protein concentrations, substrate concentrations, incubation times, and reaction termination solvents for each activity have been
described in detail previously (Walsky and Obach, 2004). Incubation mixtures contained PF-07321332 at concentrations ranging from 0.01–300 µM. Stock solutions of PF-07321332 were prepared in 90% acetonitrile 10% water. The final concentration of acetonitrile in the incubation mixtures was 0.9% (v/v). Parallel incubations were conducted to determine the IC₅₀ after a 30 min preincubation (IC₅₀ shift) (Perloff et al., 2009), where PF-07321332 was incubated with HLM and NADPH for 30 min prior to the co-incubation with marker substrate. Time dependent inhibition occurred when the IC₅₀ was ≥ 1.5 more potent after preincubation. Nonlinear regression was performed in GraphPad to determine the IC₅₀ using the following equation, where Y is the percent activity remaining, [I] is the inhibitor concentration, and Hill Slope was determined based on the fit of the data (typically 1).

\[
Y = \frac{100}{1 + 10^{(\log[I] - \log(IC50)) \cdot HillSlope}}
\]

To examine the ability of PF-07321332 to act as a time- and/or NADPH-dependent inhibitor of CYP3A, incubations were conducted in HLM (0.3 mg/ml) supplemented with MgCl₂ (3.3 mM) and NADPH (1.3 mM) in potassium phosphate buffer (100 mM, pH 7.4). PF-07321332 stock solutions, at concentrations of 0.1–100 µM (final), were prepared at 100-times the final incubation concentration in a mixture of 90% acetonitrile 10% water (final organic 0.9% acetonitrile). The incubation was initiated with the addition of PF-07321332 stock solution to the microsomal mixture. Periodic aliquots (1–40 min) of the mixture was transferred to an activity incubation mixture containing midazolam (20.9 µM, 10-fold Kᵅ), MgCl₂ (3.3 mM), and NADPH (1.3 mM) in potassium phosphate buffer (100 mM, pH 7.4), resulting in a 20-fold dilution. After 6 min, the activity reaction was terminated by the addition of two volumes of acetonitrile containing internal standard (100 ng/ml [²H₄]1'-hydroxymidazolam). Reactions were carried out at 37 °C, at a final volume of 200 µl, in duplicate. Samples were vortexed and centrifuged for 5 min at approximately 2300 x g at room temperature. The supernatant was mixed with an equal volume of water containing 0.2% formic acid and analyzed directly by LC-MS/MS. LC-MS/MS analysis was conducted on a Sciex 6500 triple quadrupole mass spectrometer fitted with an electrospray ion source operated in positive ion mode using multiple reaction monitoring. An Agilent 1290 binary pump with a CTC Leap autosampler (Leap Technology, Carrboro, NC) was programmed to inject 10 µl of sample on a Halo 2.7 µm C18 2.1x30 mm column (Advanced Materials Technology, Wilmington, DE). A binary
gradient was employed using 0.1% (v/v) formic acid in water (mobile phase A) and 0.1% (v/v) formic acid in acetonitrile (mobile phase B) at a flow rate of 0.5 ml/min. Mass-to-charge (m/z) transitions (Q1/Q3) for analytes 1’-hydroxymidazolam and [2H₄]1’-hydroxymidazolam were 342.2/324.2 and 346.2/328.2, respectively. To determine the kinetic inactivation parameters, the natural log of percent remaining activity versus preincubation time was plotted then the slope of the line (-k_{obs}) was calculated using linear regression. K_I and k_{inact} parameters were determined using nonlinear regression of the three-parameter Michaelis-Menten equation below:

\[ k_{obs} = k_{obs[0\mu M]} + \frac{k_{inact} \times [I]}{K_I + [I]} \]

[I] represents the concentrations of the test drug in the primary incubation, k_{inact} is the maximal inactivation rate, k_{obs[0\mu M]} is the inactivation rate in the solvent control, and K_I is the inactivator concentration at half k_{inact}. A similar experiment was conducted using testosterone as the CYP3A probe substrate. These incubations contained testosterone in the activity incubation mixture at 10-fold K_M (386 µM) which was carried out for a duration of 10 min. The internal standard solution contained 100 ng/ml [2H₃]6β-hydroxytestosterone. Mass-to-charge (m/z) transitions (Q1/Q3) for analytes 6β-hydroxytestosterone and [2H₃]6β-hydroxytestosterone were 305.2/269.2 and 308.2/272.7, respectively, and analytes were separated using a Halo 2 µm C18 2.1x50 mm column.

**Measurement of absorption spectra of CYP metabolic intermediate (MI) complexes.** Aliquots of recombinant human CYP3A4, oxidoreductase, cytochrome b5 supersomes (Corning, 0.3 nmol/ml final CYP concentration) and NADPH (1 mM final concentration) in 0.1 M potassium phosphate buffer containing 3.3 mM magnesium chloride (pH 7.4) were transferred to matched sample and reference cuvettes (990 µl each) in a Agilent Cary Series 100 UV-Vis spectrophotometer (Santa Clara, CA). The instrument was zeroed and baselined between 400 and 500 nm. Reactions were started by addition of 10 µl of 1 mM acetonitrile solutions of either troleandomycin (CYP3A4 inactivator and positive control) or PF-07321332 to the sample cuvette and 10 µl of acetonitrile to the reference cuvette. Spectral scans (400–500 nm) were at approximately 0, 1, 5, 10, 15, 20, 25, and 30 min.

**CYP3A4 Induction in Human Hepatocytes.** Cryopreserved human hepatocytes were used to examine CYP3A4 induction potential of PF-07321332 using established protocols (Dong et al.,
Briefly, primary cultures of human hepatocytes from four donors (BXM, BNA, FOS, and HH1144) were seeded in collagen I-precoated 24-well plates, and each well had a cell density of ~7.0 x 10^5 viable cells. Hepatocyte cultures were treated for 2 consecutive days with medium containing solvent (0.1% DMSO) control, PF-07321332 (0.01, 0.03, 0.1, 0.3, 1.0, 3.0, 10, 30, 50, 100, and 200 µM), or prototypical CYP3A4 inducer rifampicin (10 µM). Following the incubation phase of the experiment, the medium containing test compounds or vehicle was removed and the cells were washed with phosphate buffered saline and fresh medium was added to all wells for a 30 minute wash. Following removal of the wash media, midazolam (30 µM) in 0.1% DMSO was added to each well and the plate was returned to the incubator for 30 minutes. After incubation, 200 µl of the medium from each well was removed and analyzed for 1-hydroxymidazolam formation using established LC-MS/MS protocols (Walsky and Obach, 2004). Quantification of CYP3A4 messenger RNA (mRNA) was performed using the TaqMan® as previously described (Fahmi et al., 2008). Data for mRNA and activity (normalized to DMSO vehicle control) were plotted versus the concentration of the PF-07321332 or rifampin. Individual fitting was carried out on each hepatocyte donor using GraphPad Prism (version 8.0.2), and was fit to either a four-parameter sigmoidal model (fitting maximum fold induction (Ind_{max} = E_{max} + 1), Hill slope (γ), and concentration of PF-07321332 that produced half Ind_{max} (EC_{50}), with baseline fixed at 1), three-parameter sigmoidal model (fitting Ind_{max} and EC_{50}, with Hill slope and baseline each fixed at 1), or a linear function (with y intercept fixed at 1); simpler models were preferred unless adding a parameter produced a fit with a p value < 0.05 by an extra sum-of-squares F test.

**In Vitro Transporter Inhibition Assays.** The inhibition of BCRP and MDR1 was measured using membrane vesicles (Solvo Biotechnology, Budapest, Hungary). Transporter-transfected human embryonic kidney (HEK)293 cells were used to measure the inhibition for organic anion transporting polypeptide (OATP)1B1 and 1B3 (Pfizer (Groton, CT) and Pfizer (sandwich, United Kingdom), respectively), multidrug and toxin extrusion protein (MATE)1/2K (Dr. Katsuhsa Inoue, Nagoya city University, Nagoya, Japan), organic cation transporter (OCT)1/2, and organic anion transporter (OAT)1/3 (Professor Kathleen Giacomini, University of California, San Francisco, CA). A 30-min pre-incubation with PF-07321332 or a control inhibitor was performed prior to the OATP1B1/1B3 assay incubation. The assays were started by adding probe substrates in the presence or absence of PF-07321332 (8 concentrations at 0.032-
1000 μM) and control inhibitors. The cells were incubated for 1-4 min depending on the transporter. The following probe substrates were used at concentrations below their K_m values; 0.2 μM of rosuvastatin for BCRP (K_m=3.2 μM) and 0.2 μM of N-methyl quinidine for MDR1 (K_m=0.72 μM), 10 or 15 μM of metformin for MATE1/2K and OCT1/2 (K_m=1481-2596 μM), 0.5 μM of para-aminohippuric acid for OAT1 (K_m=4.97 μM), 0.1 μM of estrone-3-sulfate for OAT3 (K_m=9.46 μM), 0.3 μM of rosuvastatin for OATP1B1/1B3 (K_m=3.8/28.3 μM). Detailed procedures have been described previously (Bi et al., 2019; Boras et al., 2021; Costales et al., 2021). IC_{50} values for all transporters assays were estimated using the following equation from GraphPad Prism:

\[
\text{Percent Activity} = \text{Bottom} + \frac{(\text{Top} - \text{Bottom})}{1 + 10^{((\log IC_{50} - [\text{inhib}]) \times \text{HillSlope})}}
\]

References


Supplemental Figure 1. $^1$H NMR spectrum of PF-07321332.
Supplemental Figure 2. High-resolution mass spectral data for metabolite M1 (PF-07329265). Top panel MS\(^1\) spectrum; middle and lower panels are MS\(^2\) spectra of m/z 516 from collision-induced dissociation (CID) and high-energy C-trap dissociation (HCD), respectively.
Supplementary Figure 3. $^1$H NMR spectrum of M1 (PF-07329265).
**Supplementary Figure 4.** Comparison of the $^1$H-$^{13}$C HSQC of PF-07321332 (panel B) and M1 (PF-07329265) (panel C), $^1$H NMR spectrum of PF-07329265 at 340 °K (panel D), 1D ROE spectra of PF-07329265 at 340 °K, C10 methylene irradiated, δ 3.32, (panel E), 1D ROE spectrum of PF-07329265 at 340 °K, C9 methyl irradiated, δ 0.86 (panel F).
Supplementary Figure 5. Energy minimized three dimensional structure of metabolite M1 (PF-07329265).
Supplemental Figure 6. High-resolution mass spectral data for metabolite M2 (PF-07329266). Top panel MS\(^1\) spectrum; middle and lower panels are MS\(^2\) spectra of \(m/z\) 516 from CID and HCD, respectively.
Supplementary Figure 7. $^1$H NMR spectrum of metabolite M2 (PF-07329266).
Supplementary Figure 8. High-resolution mass spectra data for metabolite M3 (PF-07329267).

Top panel MS$^1$ spectrum; middle and lower panels are MS$^2$ spectra of $m/z$ 516 from CID and HCD, respectively.
Supplementary Figure 9. $^1$H NMR spectrum of metabolite M3 (PF-07329267).
Supplementary Figure 10. $^{1}H^{13}C$ HSQC NMR spectrum of metabolite M3 (PF-07329267).
Supplemental Figure 11. High-resolution mass spectral data for metabolite M4 (PF-07329268).

Top panel MS\(^1\) spectrum; middle and lower panels are MS\(^2\) spectra of m/z 498 from CID and HCD, respectively.
Supplemental Figure 12. $^1$H NMR spectrum of metabolite M4 (PF-07329268).
Supplemental Figure 13. 1H-13C HSQC spectral data for metabolite M4 (PF-07329268).
**Supplemental Figure 14.** High-resolution mass spectral data for dehydrogenated metabolite m/z 498. Top panel MS\(^1\) spectrum; Middle and lower panels are MS\(^2\) spectra of m/z 498 from CID and HCD, respectively.
Supplemental Figure 15. Eadie-Hofstee plots for the formation of the primary PF-07321332 metabolites PF-07329265 (M1), PF-07329266 (M2), PF-07329267 (M3), and PF-07329268 (M4) following incubation of PF-07321332 (0.02–200 μM) with HLM (0.3 mg/ml).
Supplemental Figure 16. IV and PO single dose PK for PF-07321332 in rats (Panel A) and monkeys (Panel B). Oral pharmacokinetics were conducted with crystalline PF-07321332 as MTBE co-solvate (rats and monkeys) and anhydrous form 1 (rats).
Supplementary Figure 17. Measurement of absorption spectra of CYP metabolic intermediate (MI) complexes following incubation of PF-07321332 and positive control troleandomycin with recombinant human CYP3A4, oxidoreductase, and cytochrome b5 supersomes. Spectral scans (400-500 nm) by UV-Vis spectroscopy were obtained at ~ 0, 1, 5, 10, 15, 20, 25, and 30 min.
**Supplemental Table 1.** Permeability of PF-07321332 across caco-2 cell monolayers.

<table>
<thead>
<tr>
<th>Nominal PF-07321332 Concentration (µM)</th>
<th>Mean A-B Permeability (SD) (×10⁻⁶ cm/sec)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.11</td>
<td>0.66 (0.17)</td>
</tr>
<tr>
<td>0.32</td>
<td>0.80 (0.15)</td>
</tr>
<tr>
<td>0.95</td>
<td>0.82 (0.20)</td>
</tr>
<tr>
<td>2.85</td>
<td>0.92 (0.16)</td>
</tr>
<tr>
<td>8.55</td>
<td>0.76 (0.02)</td>
</tr>
<tr>
<td>25.65</td>
<td>0.72 (0.08)</td>
</tr>
<tr>
<td>77.00</td>
<td>1.14 (0.19)</td>
</tr>
<tr>
<td>231.0</td>
<td>1.19 (0.13)</td>
</tr>
<tr>
<td>0.32 + 10 µM efflux inhibitor cocktaila</td>
<td>4.05 (0.26)</td>
</tr>
</tbody>
</table>

*a Inhibitor cocktail = 10 µM Ko143, 10 µM PSC833, 100 µM MK571.*
**Supplemental Table 2.** Permeability and efflux ratios of PF-07321332 in MDCKI-MDR1 and MDCKII-BCRP cells.

<table>
<thead>
<tr>
<th>Compound</th>
<th>$P_{\text{app}}$ AB (SD) (x 10$^{-6}$ cm/s)</th>
<th>$P_{\text{app}}$ BA (SD) (x 10$^{-6}$ cm/s)</th>
<th>Efflux Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MDCKI-MDR1</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PF-07321332 (0.3 μM)</td>
<td>0.21 (0.01)</td>
<td>9.94 (0.47)</td>
<td>48.4</td>
</tr>
<tr>
<td>PF-07321332 (0.3 μM) + PSC833 (5.0 μM)</td>
<td>0.75 (0.10)</td>
<td>1.45 (0.12)</td>
<td>1.9</td>
</tr>
<tr>
<td>PF-07321332 (1.0 μM)</td>
<td>0.12 (0.02)</td>
<td>10.25 (0.34)</td>
<td>83.7</td>
</tr>
<tr>
<td>PF-07321332 (1.0 μM) + PSC833 (5.0 μM)</td>
<td>0.79 (0.07)</td>
<td>1.34 (0.24)</td>
<td>1.7</td>
</tr>
<tr>
<td>PF-07321332 (3.0 μM)</td>
<td>0.14 (0.03)</td>
<td>10.03 (0.61)</td>
<td>71.1</td>
</tr>
<tr>
<td>PF-07321332 (3.0 μM) + PSC833 (5.0 μM)</td>
<td>0.62 (0.09)</td>
<td>1.41 (0.20)</td>
<td>2.3</td>
</tr>
<tr>
<td>Quinidine (0.5 μM)</td>
<td>1.36 (0.16)</td>
<td>78.22 (0.57)</td>
<td>57.6</td>
</tr>
<tr>
<td>Quinidine (0.5 μM) + PSC833 (5.0 μM)</td>
<td>21.37 (0.93)</td>
<td>19.77 (0.78)</td>
<td>0.9</td>
</tr>
<tr>
<td><strong>MDCKII-BCRP</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PF-07321332 (0.3 μM)</td>
<td>1.25 (0.03)</td>
<td>1.82 (0.24)</td>
<td>1.5</td>
</tr>
<tr>
<td>PF-07321332 (1.0 μM)</td>
<td>1.17 (0.04)</td>
<td>1.81 (0.19)</td>
<td>1.5</td>
</tr>
<tr>
<td>PF-07321332 (3.0 μM)</td>
<td>1.22 (0.08)</td>
<td>1.77 (0.17)</td>
<td>1.4</td>
</tr>
<tr>
<td>Pitavastatin (0.5 μM)</td>
<td>0.44 (0.26)</td>
<td>11.08 (1.35)</td>
<td>24.9</td>
</tr>
<tr>
<td>Pitavastatin (0.5 μM) + Ko143 (5 μM)</td>
<td>4.55 (0.36)</td>
<td>0.87 (0.10)</td>
<td>0.2</td>
</tr>
</tbody>
</table>
**Supplemental Table 3.** Plasma protein binding of PF-07321332.

<table>
<thead>
<tr>
<th>Species (strain)</th>
<th>$f_{u,p}^a$ 0.3 µM</th>
<th>$f_{u,p}^a$ 1.0 µM</th>
<th>$f_{u,p}^a$ 3.0 µM</th>
<th>$f_{u,p}^a$ 10 µM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat (Wistar-Han)</td>
<td>0.490</td>
<td>0.474</td>
<td>0.484</td>
<td>0.467</td>
</tr>
<tr>
<td>Monkey (Cynomolgus)</td>
<td>0.386</td>
<td>0.404</td>
<td>0.449</td>
<td>0.499</td>
</tr>
<tr>
<td>Human</td>
<td>0.296</td>
<td>0.300</td>
<td>0.311</td>
<td>0.333</td>
</tr>
</tbody>
</table>

$^a$Geometric mean ($n=12$).
### Supplemental Table 4. IC$_{50}$ values for the reversible inhibition of major human cytochrome P450 (CYP) enzyme activities in HLM by PF-07321332.$^a$

<table>
<thead>
<tr>
<th>CYP Enzyme</th>
<th>Enzyme Reaction</th>
<th>T$<em>0$ Mean IC$</em>{50}$ (95% Confidence Interval, $\mu$M)$^b$</th>
<th>T$<em>{30}$ Mean IC$</em>{50}$ (95% Confidence Interval, $\mu$M)$^c$</th>
</tr>
</thead>
<tbody>
<tr>
<td>1A2</td>
<td>Phenacetin $O$-dealkylation</td>
<td>$&gt;300$</td>
<td>$&gt;300$</td>
</tr>
<tr>
<td>2B6</td>
<td>Bupropion hydroxylation</td>
<td>$&gt;300$</td>
<td>$&gt;300$</td>
</tr>
<tr>
<td>2C8</td>
<td>Amodiaquine $N$-dealkylation</td>
<td>$&gt;300$</td>
<td>$&gt;300$</td>
</tr>
<tr>
<td>2C9</td>
<td>Diclofenac 4’-hydroxylation</td>
<td>$&gt;300$</td>
<td>$&gt;300$</td>
</tr>
<tr>
<td>2C19</td>
<td>$S$-Mephenytoin 4’-hydroxylation</td>
<td>$&gt;300$</td>
<td>$&gt;300$</td>
</tr>
<tr>
<td>2D6</td>
<td>Dextromethorphan $O$-demethylation</td>
<td>$&gt;300$</td>
<td>$&gt;300$</td>
</tr>
<tr>
<td>3A4/5</td>
<td>Midazolam 1’-hydroxylation</td>
<td>58.3 (46.0–74.5)</td>
<td>27.4 (22.8–33.0)</td>
</tr>
<tr>
<td>3A4/5</td>
<td>Testosterone 6β-hydroxylation</td>
<td>106 (75.6–160)</td>
<td>61.1 (53.5–69.9)</td>
</tr>
<tr>
<td>3A4/5</td>
<td>Nifedipine oxidation</td>
<td>45.1 (35.4–58.0)</td>
<td>36.6 (29.4–45.8)</td>
</tr>
</tbody>
</table>

$^a$Incubations with PF-07321332 (0.01–300 $\mu$M) and marker CYP substrates were conducted in NADPH (1.3 mM)-supplemented pooled HLM in the presence of MgCl$_2$ (3.3 mM) in potassium phosphate buffer (100 mM, pH 7.4). Marker CYP substrate concentrations were near enzyme affinity or Michaelis constant (K$_m$) values that had been previously determined and incubation times were selected based on previous determinations of reaction velocity linearity (Walsky and Obach, 2004). Incubations were conducted in duplicate and a solvent control (90/10 acetonitrile/water) was also tested. Detailed protocols including analysis of marker CYP substrate activities have been previously published (Walsky and Obach, 2004).

$^b$Zero-minute preincubation (T$_0$) IC$_{50}$ values.

$^c$30-minute preincubation (T$_{30}$) IC$_{50}$ values. A >1.5–fold shift in IC$_{50}$ (between T$_0$ and T$_{30}$) of 2.13 (midazolam 1’-hydroxylation), 1.73 (testosterone 6β-hydroxylation), and 1.23 (nifedipine oxidation) for CYP3A4 activity was observed, which was suggestive of the potential for time-dependent inhibition (Perloff et al., 2009) of CYP3A4 by PF-07321332.
**Supplemental Table 5.** Kinetic Parameters for the time-, concentration-, and NADPH-dependent inhibition of CYP3A4/5 by PF-07321332 in NADPH-fortified HLM.

<table>
<thead>
<tr>
<th>Probe Substrate</th>
<th>$K_I \pm SE$ (μM)$^a$</th>
<th>$k_{\text{inact}} \pm SE$ (min$^{-1}$)$^b$</th>
<th>$k_{\text{inact}}/K_I \pm SE$ (ml min$^{-1}$ μmol$^{-1}$)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Midazolam</td>
<td>15.5 ± 4.9</td>
<td>0.0142 ± 0.0013</td>
<td>0.916 ± 0.302</td>
</tr>
<tr>
<td>Testosterone</td>
<td>13.9 ± 3.0</td>
<td>0.0165 ± 0.0010</td>
<td>1.23 ± 0.29</td>
</tr>
</tbody>
</table>

$^a$K$_I$ = apparent inactivation concentration at half-maximal rate of inactivation. $^b$k$_{\text{inact}}$ = maximal inactivation rate. SE = standard error. Inactivation constants K$_I$ and k$_{\text{inact}}$ was calculated from the nonlinear regression of a three-parameter Michaelis-Menten equation using GraphPad.
**Supplemental Table 6.** EC$_{50}$, $E_{\text{max}}$, and $\gamma$ (Hill slope) (± standard error (SE))$^a$ for induction of CYP3A4 mRNA and midazolam-1’-hydroxylase activity by PF-07321332 in human hepatocytes.

<table>
<thead>
<tr>
<th>Donor</th>
<th>CYP3A4 mRNA$^b$</th>
<th>CYP3A4 Activity$^b$</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>EC$_{50}$ ± SE (μM)</td>
<td>Ind$_{\text{max}}$ ± SE</td>
</tr>
<tr>
<td>BXM</td>
<td>25.4 ± 2.0</td>
<td>30.3 ± 1.1</td>
</tr>
<tr>
<td>BNA</td>
<td>17.6 ± 1.3</td>
<td>33.7 ± 0.8</td>
</tr>
<tr>
<td>FOS</td>
<td>15.7 ± 10.8</td>
<td>18.0 ± 3.0</td>
</tr>
<tr>
<td>HH1144</td>
<td>30.9 ± 6.1</td>
<td>47.6 ± 2.9</td>
</tr>
</tbody>
</table>

$^a$SE for PF-07321332 parameters reflects fit parameter uncertainty; Standard error (SE) for rifampin parameters determined by variability in fit parameters obtained for each independent run. $^b$fold induction in CYP3A4 mRNA or enzyme activity (midazolam-1’-hydroxylase) in human hepatocytes expressed as pmol/min/10$^6$ cells. $^c$n = number of replicates (for PF-07321332). $^d$where tabulated $\gamma \neq 1.0$, CYP3A4 mRNA and activity data was fit using a four-parameter sigmoidal model; otherwise data was fit using a three-parameter sigmoidal model. $^e$ND = not determined due to lack of changes (induction) in midazolam-1’-hydroxylase activity.
Supplemental Table 7. IC<sub>50</sub> values for the reversible inhibition of major human intestinal, hepatobiliary, and renal transporters by PF-07321332.

<table>
<thead>
<tr>
<th>Reagent System&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Transporter&lt;sup&gt;b&lt;/sup&gt;</th>
<th>Substrate</th>
<th>PF-07321332 concentration (µM)</th>
<th>IC&lt;sub&gt;50&lt;/sub&gt; (µM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HEK293 vesicles</td>
<td>BCRP</td>
<td>Rosuvastatin (0.2 µM)</td>
<td>0.032-1000</td>
<td>&gt; 1000</td>
</tr>
<tr>
<td>HEK293 cells</td>
<td>MATE1</td>
<td>[&lt;sup&gt;14&lt;/sup&gt;C]-metformin (15 µM)</td>
<td>0.061-1000</td>
<td>112</td>
</tr>
<tr>
<td>HEK293 cells</td>
<td>MATE2K</td>
<td>[&lt;sup&gt;14&lt;/sup&gt;C]-metformin (15 µM)</td>
<td>0.061-1000</td>
<td>872</td>
</tr>
<tr>
<td>HEK293 vesicles</td>
<td>MDR1</td>
<td>N-methylquinidine (0.2 µM)</td>
<td>0.032-1000</td>
<td>71</td>
</tr>
<tr>
<td>HEK293 cells</td>
<td>OAT1</td>
<td>[&lt;sup&gt;3&lt;/sup&gt;H]-PAH (0.5 µM)</td>
<td>0.032-1000</td>
<td>&gt; 1000</td>
</tr>
<tr>
<td>HEK293 cells</td>
<td>OAT3</td>
<td>[&lt;sup&gt;3&lt;/sup&gt;H]-ES (0.1 µM)</td>
<td>0.032-1000</td>
<td>521</td>
</tr>
<tr>
<td>HEK293 cells</td>
<td>OATP1B1</td>
<td>Rosuvastatin (0.3 µM)</td>
<td>0.032-1000</td>
<td>44</td>
</tr>
<tr>
<td>HEK293 cells</td>
<td>OATP1B3</td>
<td>Rosuvastatin (0.3 µM)</td>
<td>0.032-1000</td>
<td>283</td>
</tr>
<tr>
<td>HEK293 cells</td>
<td>OCT1</td>
<td>[&lt;sup&gt;14&lt;/sup&gt;C]-metformin (10 µM)</td>
<td>0.032-1000</td>
<td>138</td>
</tr>
<tr>
<td>HEK293 cells</td>
<td>OCT2</td>
<td>[&lt;sup&gt;14&lt;/sup&gt;C]-metformin (15 µM)</td>
<td>0.061-1000</td>
<td>954</td>
</tr>
</tbody>
</table>

<sup>a</sup>HEK = human embryonic kidney. Marker transporter substrate concentration used at its respective K<sub>m</sub> for that transporter. PAH = para-aminohippuric acid, ES = estrone-3-sulfate
### Supplemental Table 8.

Toxicokinetic parameters for orally administered PF-07321332-MTBE co-solvent in rats and monkeys in a 2-week regulatory toxicology study.

<table>
<thead>
<tr>
<th>Species</th>
<th>Day</th>
<th>Daily Oral Dose (mg/kg)</th>
<th>C&lt;sub&gt;max&lt;/sub&gt; (μg/mL)</th>
<th>T&lt;sub&gt;max&lt;/sub&gt; (h)</th>
<th>AUC&lt;sub&gt;24&lt;/sub&gt; (μg·h/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>total</td>
<td>unbound</td>
<td>total</td>
</tr>
<tr>
<td><strong>Rat</strong></td>
<td>1</td>
<td>60 QD</td>
<td>12.9 ± 1.9</td>
<td>6.18</td>
<td>0.5 ± 0.0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>200 QD</td>
<td>37.0 ± 4.0</td>
<td>17.7</td>
<td>0.5 ± 0.0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1000 QD</td>
<td>62.1 ± 5.5</td>
<td>29.7</td>
<td>2.0 ± 1.5</td>
</tr>
<tr>
<td></td>
<td>14</td>
<td>60 QD</td>
<td>13.3 ± 5.0</td>
<td>6.37</td>
<td>0.5 ± 0.0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>200 QD</td>
<td>27.1 ± 3.3</td>
<td>13.0</td>
<td>0.5 ± 0.0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1000 QD</td>
<td>51.5 ± 0.9</td>
<td>24.7</td>
<td>2.0 ± 0.0</td>
</tr>
<tr>
<td><strong>Monkey</strong></td>
<td>1</td>
<td>20 BID</td>
<td>1.79 ± 0.89</td>
<td>0.779</td>
<td>1.3 ± 0.6</td>
</tr>
<tr>
<td></td>
<td></td>
<td>50 BID</td>
<td>11.3 ± 6.1</td>
<td>4.92</td>
<td>1.3 ± 1.3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>300 BID</td>
<td>59.6 ± 11.8</td>
<td>25.9</td>
<td>3.0 ± 1.1</td>
</tr>
<tr>
<td></td>
<td>15</td>
<td>20 BID</td>
<td>2.42 ± 0.50</td>
<td>1.05</td>
<td>0.67 ± 0.26</td>
</tr>
<tr>
<td></td>
<td></td>
<td>50 BID</td>
<td>11.8 ± 6.6</td>
<td>5.13</td>
<td>0.92 ± 0.58</td>
</tr>
<tr>
<td></td>
<td>300 BID</td>
<td>106 ± 18</td>
<td>46.1</td>
<td>3.7 ± 0.8</td>
<td>1220 ± 224</td>
</tr>
<tr>
<td>---</td>
<td>---------</td>
<td>----------</td>
<td>------</td>
<td>-----------</td>
<td>------------</td>
</tr>
</tbody>
</table>